China Biologic Products 10-K 12 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 12, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'CBPO	'	'
Entity Common Stock, Shares Outstanding	'	23,367,665	'
Entity Registrant Name	'China Biologic Products, Inc.	'	'
Entity Central Index Key	'0001369868	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$175

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$144,138,487	$129,609,317
Time deposit	6,608,612	0
Accounts receivable, net of allowance for doubtful accounts	17,270,132	11,206,244
Inventories	88,634,855	75,679,173
Prepayments and other current assets	7,641,061	5,664,919
Total Current Assets	264,293,147	222,159,653
Property, plant and equipment, net	73,149,072	51,325,177
Intangible assets, net	2,585,232	3,541,582
Land use rights, net	8,213,145	5,818,709
Deposits related to land use rights	13,667,130	14,752,574
Restricted cash and deposit	30,523,674	2,912,145
Equity method investment	11,349,807	10,537,310
Total Assets	403,781,207	311,047,150
Current liabilities	'	'
Short-term bank loans	9,822,000	7,935,000
Accounts payable	4,445,732	2,908,624
Due to related parties	7,206,970	4,081,624
Other payables and accrued expenses	34,852,740	25,423,349
Advance from customers	2,908,853	2,857,420
Income tax payable	4,202,405	4,513,075
Total Current Liabilities	63,438,700	47,719,092
Long-term bank loans	30,000,000	0
Deferred income	3,003,895	2,912,145
Other liabilities	3,369,003	2,996,749
Total Liabilities	99,811,598	53,627,986
Stockholders' Equity	'	'
Common stock: par value $0.0001; 100,000,000 shares authorized; 27,341,744 and 26,629,615 shares issued at December 31, 2013 and 2012, respectively; 25,862,040 and 26,629,615 shares outstanding at December 31, 2013 and 2012, respectively	2,734	2,663
Additional paid-in capital	72,031,864	62,251,731
Treasury stock: 1,479,704 and nil shares at December 31, 2013 and 2012, respectively, at cost	-29,594,080	0
Retained earnings	173,744,551	119,143,000
Accumulated other comprehensive income	21,506,494	14,072,322
Total equity attributable to China Biologic Products, Inc.	237,691,563	195,469,716
Noncontrolling interest	66,278,046	61,949,448
Total Stockholders’ Equity	303,969,609	257,419,164
Commitments and contingencies	0	0
Total Liabilities and Stockholders’ Equity	$403,781,207	$311,047,150

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,341,744	26,629,615
Common Stock, Shares, Outstanding	25,862,040	26,629,615
Treasury Stock, Shares	1,479,704	0

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales	$203,356,856	$184,813,495	$153,092,289
Cost of sales	65,484,153	58,835,998	46,017,661
Gross profit	137,872,703	125,977,497	107,074,628
Operating expenses	'	'	'
Selling expenses	10,643,149	14,421,258	14,595,794
General and administrative expenses	36,073,871	34,034,360	31,519,824
Research and development expenses	4,223,165	3,032,719	3,978,233
Impairment loss of goodwill	0	0	18,160,281
Loss on abandonment and write-off of long-lived assets	0	0	6,603,028
Income from operations	86,932,518	74,489,160	32,217,468
Other income (expenses)	'	'	'
Equity in income of an equity method investee	2,170,473	2,665,881	1,858,171
Change in fair value of derivative liabilities	0	1,769,140	11,974,834
Interest income	4,433,326	2,910,297	1,356,950
Interest expense	-1,134,952	-1,269,850	-4,670,606
Other income (expense), net	0	570,511	-453,949
Total other income, net	5,468,847	6,645,979	10,065,400
Earnings before income tax expense	92,401,365	81,135,139	42,282,868
Income tax expense	15,540,301	15,163,147	10,899,513
Net income	76,861,064	65,971,992	31,383,355
Less: Net income attributable to noncontrolling interest	22,259,513	20,749,803	13,201,645
Net income attributable to China Biologic Products, Inc.	54,601,551	45,222,189	18,181,710
Net income per share of common stock:	'	'	'
Basic	$2.05	$1.73	$0.73
Diluted	$1.96	$1.62	$0.37
Weighted average shares used in computation:	'	'	'
Basic	26,410,819	26,153,540	25,028,796
Diluted	27,572,111	26,839,723	26,654,662
Net income	76,861,064	65,971,992	31,383,355
Other comprehensive income:	'	'	'
Foreign currency translation adjustment, net of nil income taxes	9,126,218	1,735,492	6,846,721
Comprehensive income	85,987,282	67,707,484	38,230,076
Less: Comprehensive income attributable to noncontrolling interest	23,951,559	21,163,655	15,320,805
Comprehensive income attributable to China Biologic Products, Inc.	$62,035,723	$46,543,829	$22,909,271

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated other comprehensive income [Member]	Equity Attributable To China Biologic Products, Inc. [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2010	$145,044,133	$2,435	$35,435,139	$55,739,101	$0	$8,023,121	$99,199,796	$45,844,337
Balance (in shares) at Dec. 31, 2010	'	24,351,125	'	'	'	'	'	'
Net income	31,383,355	0	0	18,181,710	0	0	18,181,710	13,201,645
Other comprehensive income	6,846,721	0	0	0	0	4,727,561	4,727,561	2,119,160
Dividend declared by subsidiaries to noncontrolling interest	-14,766,400	0	0	0	0	0	0	-14,766,400
Acquisition of noncontrolling interests	-7,635,000	0	-4,764,935	0	0	0	-4,764,935	-2,870,065
Share-based compensation	4,896,232	0	4,896,232	0	0	0	4,896,232	0
Common stock issued in connection with:	'	'	'	'	'	'	'	'
Exercise of warrants	0	0	0	0	0	0	0	0
Exercise of warrants (Shares)	'	0	'	'	'	'	'	'
Exercise of stock options	300,000	8	299,992	0	0	0	300,000	0
Exercise of stock options (in shares)	75,000	75,000	'	'	'	'	'	'
Conversion of convertible notes	12,972,000	117	12,971,883	0	0	0	12,972,000	0
Conversion of convertible notes (Shares)	'	1,175,000	'	'	'	'	'	'
Balance at Dec. 31, 2011	179,041,041	2,560	48,838,311	73,920,811	0	12,750,682	135,512,364	43,528,677
Balance (in shares) at Dec. 31, 2011	'	25,601,125	'	'	'	'	'	'
Net income	65,971,992	0	0	45,222,189	0	0	45,222,189	20,749,803
Other comprehensive income	1,735,492	0	0	0	0	1,321,640	1,321,640	413,852
Dividend declared by subsidiaries to noncontrolling interest	-2,742,884	0	0	0	0	0	0	-2,742,884
Share-based compensation	4,544,927	0	4,544,927	0	0	0	4,544,927	0
Common stock issued in connection with:	'	'	'	'	'	'	'	'
Exercise of warrants	8,141,279	94	8,141,185	0	0	0	8,141,279	0
Exercise of warrants (Shares)	'	937,500	'	'	'	'	'	'
Exercise of stock options	727,317	9	727,308	0	0	0	727,317	0
Exercise of stock options (in shares)	90,990	90,990	'	'	'	'	'	'
Balance at Dec. 31, 2012	257,419,164	2,663	62,251,731	119,143,000	0	14,072,322	195,469,716	61,949,448
Balance (in shares) at Dec. 31, 2012	'	26,629,615	'	'	'	'	'	'
Net income	76,861,064	0	0	54,601,551	0	0	54,601,551	22,259,513
Other comprehensive income	9,126,218	0	0	0	0	7,434,172	7,434,172	1,692,046
Dividend declared by subsidiaries to noncontrolling interest	-18,323,710	0	0	0	0	0	0	-18,323,710
Acquisition of noncontrolling interests	-1,963,913	0	-664,662	0	0	0	-664,662	-1,299,251
Share repurchase	-29,594,080	0	0	0	-29,594,080	0	-29,594,080	0
Share-based compensation	5,050,796	0	5,050,796	0	0	0	5,050,796	0
Common stock issued in connection with:	'	'	'	'	'	'	'	'
Exercise of stock options	5,394,070	65	5,394,005	0	0	0	5,394,070	0
Exercise of stock options (in shares)	648,379	648,379	'	'	'	'	'	'
Vesting of restricted shares	0	6	-6	0	0	0	0	0
Vesting of restricted shares (in shares)	'	63,750	'	'	'	'	'	'
Balance at Dec. 31, 2013	$303,969,609	$2,734	$72,031,864	$173,744,551	($29,594,080)	$21,506,494	$237,691,563	$66,278,046
Balance (in shares) at Dec. 31, 2013	'	27,341,744	'	'	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net income	$76,861,064	$65,971,992	$31,383,355
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation	6,096,650	5,792,418	4,253,661
Amortization	1,365,734	3,088,320	3,394,808
(Gain) loss on sale of property, plant and equipment	-123,777	828,296	166,934
Impairment loss of goodwill	0	0	18,160,281
Loss on abandonment and write-off of long-lived assets	0	0	6,603,028
Provision for (reversal of) allowance for doubtful accounts, net	31,567	-1,904	-19,611
Provision for (reversal of) doubtful accounts - other receivables and prepayments	65,094	110,123	-10,254
Write-down of obsolete inventories	0	0	270,929
Deferred tax expense (benefit)	112,632	1,127,433	-2,595,103
Share-based compensation	5,050,796	4,544,927	4,896,232
Change in fair value of derivative liabilities	0	-1,769,140	-11,974,834
Amortization of deferred note issuance cost	0	0	91,945
Amortization of discount on convertible notes	0	0	3,503,767
Equity in income of an equity method investee	-2,170,473	-2,665,881	-1,858,171
Change in operating assets and liabilities:	'	'	'
Accounts receivable	-5,667,386	5,689,638	-6,126,742
Prepayment and other current assets	-624,159	-268,498	-711,740
Inventories	-10,432,492	-3,750,200	-17,079,263
Accounts payable	1,621,917	-2,184,674	431,836
Other payables and accrued expenses	2,534,476	-3,210,777	6,061,066
Advance from customers	-38,086	-2,034,138	1,140,386
Due to related parties	66,349	734,037	0
Income tax payable	-446,911	-904,655	-1,512,591
Net cash provided by operating activities	74,302,995	71,097,317	38,469,919
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Payment for property, plant and equipment	-20,492,159	-13,886,045	-7,968,870
Payment for intangible assets and land use rights	-1,327,148	-14,059,397	-424,971
Refund of deposits related to land use right	2,100,150	0	0
Dividends received	565,425	1,109,115	1,209,880
Purchase of time deposit	-6,608,612	0	0
Proceeds from sale of property, plant and equipment	194,749	83,134	56,709
Net cash used in investing activities	-25,567,595	-26,753,193	-7,127,252
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from stock option exercised	5,394,070	727,317	300,000
Proceeds from warrants exercised	0	4,500,000	0
Payment for share repurchase	-29,594,080	0	0
Proceeds from short-term bank loans	9,693,000	11,076,100	18,595,200
Repayment of short-term bank loans	-8,014,000	-14,286,800	-10,847,200
Proceeds from long-term bank loans	30,000,000	0	0
Payment for deposit as security for long-term bank loans	-30,000,000	0	0
Acquisition of noncontrolling interest	-1,963,913	0	-7,635,000
Dividends paid by subsidiaries to noncontrolling interest	-16,931,149	-7,120,693	-10,489,504
Contribution from noncontrolling interest	2,891,422	0	0
Net cash used in financing activities	-38,524,650	-5,104,076	-10,076,504
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	4,318,420	957,434	3,204,304
NET INCREASE IN CASH AND CASH EQUIVALENTS	14,529,170	40,197,482	24,470,467
Cash and cash equivalents at beginning of year	129,609,317	89,411,835	64,941,368
Cash and cash equivalents at end of year	144,138,487	129,609,317	89,411,835
Supplemental cash flow information	'	'	'
Cash paid for income taxes	15,947,939	14,940,369	15,007,206
Cash paid for interest expense	347,602	446,381	890,312
Noncash investing and financing activities:	'	'	'
Convertible notes conversion	0	0	12,972,000
Transfer from prepayments and deposits to property, plant and equipment	7,728,824	38,452	959,660
Land use right acquired with prepayments made in prior periods	1,147,561	0	312,060
Acquisition of property, plant and equipment included in payables	4,252,428	104,300	83,226
Exercise of warrants that were liability classified	0	3,641,279	0
Restricted cash spent for property, plant and equipment	$2,928,421	$0	$0

DESCRIPTION_OF_BUSINESS_AND_SI

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	12 Months Ended
	Dec. 31, 2013
Basis Of Presentation Significant Concentration and Risks [Abstract]	'
DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	'
	NOTE 1 – DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS
	China Biologic Products, Inc. (“CBP”) and its subsidiaries (collectively, the “Company”), through its subsidiaries in the People’s Republic of China (the “PRC”), is a biopharmaceutical company that is principally engaged in the research, development, manufacturing and sales of plasma-based pharmaceutical products in the PRC. The PRC subsidiaries own and operate plasma stations that purchase and collect plasma from individual donors. The plasma is processed into finished goods after passing through a series of fractionating processes. All of the Company’s plasma products are prescription medicines that require government approval before the products are sold to customers. The Company primarily sells its products to hospitals and inoculation centers directly or through distributors in the PRC.
	Cash Concentration
	The Company maintains cash balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States. Cash balances maintained at financial institutions or state-owned banks in the PRC are not covered by insurance. Total cash at banks and deposits as of December 31, 2013 and December 31, 2012 amounted to $180,858,848 and $129,289,461, respectively, of which $679,022 and $76,101 are insured, respectively. The Company has not experienced any losses in uninsured bank deposits and does not believe that it is exposed to any significant risks on cash held in bank accounts.
	Sales Concentration
	The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 44.1%, 44.6% and 54.5% of the total sales for the years ended December 31, 2013, 2012 and 2011, respectively. IVIG accounted for 38.0%, 39.0% and 32.3% of the total sales for the years ended December 31, 2013, 2012 and 2011, respectively. If the market demands for human albumin and IVIG cannot be sustained in the future or the price of human albumin and IVIG decreases, the Company’s operating results could be adversely affected.
	Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of sales during the years ended December 31, 2013, 2012 and 2011. No individual customer represented 10% or more of trade receivables as at December 31, 2013 and 2012. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers.
	Purchase Concentration
	There were no suppliers that comprised 10% or more of the total purchases during the year ended December 31, 2013 and 2012, respectively. Two vendors comprised 10% or more of the Company’s total purchases during the year ended December 31, 2011. There were no vendors that represented more than 10% of accounts payables as at December 31, 2013. Two vendors individually represented more than 10% of accounts payables as at December 31, 2012.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation and Basis of Presentation
	The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation. The Company has no involvement with variable interest entities. The Company accounts for investments over which it has significant influence but not a controlling financial interest using the equity method of accounting.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of fixed assets; the allowance for doubtful accounts; the fair value determinations of financial and equity instruments and the valuation of share-based compensation, assets acquired and liabilities assumed in a business combination, deferred tax assets and inventories; the recoverability of goodwill, intangible asset, land use right and property, plant and equipment; and reserves for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions.
	Foreign Currency Translation
	The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income.
	Revenue Recognition
	Revenue represents the invoiced value of products sold, net of value added taxes (VAT).
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred and the customer takes ownership and assumes risk of loss, the sales price is fixed or determinable and collection of the relevant receivable is probable. The Company mainly sells human albumin and human immunoglobulin to hospitals, inoculation centers and pharmaceutical distributors. For all sales, the Company requires a signed contract or purchase order, which specify pricing, quantity and product specifications. Delivery of the product occurs when the customer receives the product, which is when the risks and rewards of ownership have been transferred. Delivery is evidenced by signed customer acknowledgement. The Company’s sales agreements do not provide the customer the right of return, unless the product is defective in which case the Company allows for an exchange of product or return. For the periods presented, defective product returns were immaterial.
	Fair Value Measurements
	The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
	•        Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date.
	•        Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
	•        Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
	The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	See Note 18 to the Consolidated Financial Statements.
	Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. Cash and cash equivalents include $74,352,540 and $20,631,000 of certificates of deposit with an initial term of three months or less at December 31, 2013 and 2012.
	As of December 31, 2013 and 2012, the Company maintained cash at banks in the following locations:
			December 31, 2013	December 31, 2012
			USD	USD
	PRC, excluding Hong Kong		143,047,540	129,213,360
	U.S.		679,022	76,101
	Total		143,726,562	129,289,461
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers.
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. Cost of work in progress and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost. Repair and maintenance costs are expensed as incurred.
	Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Estimated useful lives of the assets are as follows:
	Buildings	30 years
	Machinery and equipment	10 years
	Furniture, fixtures, office equipment and vehicles	5-10 years
	Equity Method Investment
	Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20% and 50%, and other factors, such as representation on the board of directors and participation in policy-making processes, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the Company’s share of the investee’s results of operations is included in other income (expenses) in the Company’s consolidated statements of comprehensive income. Deferred taxes are provided for the difference between the book and tax basis of the investment. The Company recognizes a loss if it is determined that other than temporary decline in the value of the investment exists. The process of assessing and determining whether an impairment on a particular equity investment is other than temporary requires a significant amount of judgment. To determine whether an impairment is other-than-temporary, management considers whether the Company has the ability and intent to hold the investment until recovery and whether evidence indicating the carrying value of the investment is recoverable outweighs evidence to the contrary. No impairment loss was recognized by the Company for the years ended December 31, 2013, 2012 and 2011.
	Intangible Assets
	Intangible assets are stated at cost less accumulated amortization. Amortization expense is recognized on the straight-line basis over the assets’ estimated useful life, as the pattern in which the economic benefits of the intangible assets are used up cannot be reliably determined. The estimated useful life is the period over which the intangible asset is expected to contribute directly or indirectly to the future cash flows of the Company. The Company has no intangible assets with indefinite useful lives. The estimate useful lives of intangible assets are as follows:
	Permits and licenses	10 years
	GMP Certificate	5 years
	Long-term customer-relationship	4 years
	Land Use Rights
	Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 to 50 years.
	Research and Development Expenses
	Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2013, 2012 and 2011 were $4,223,165, $3,032,719 and $3,978,233, respectively. These expenses include the costs of the Company’s internal research and development activities.
	Product Liability
	The Company’s products are covered by two separate product liability insurances each with coverages of approximately $3,274,000 (or RMB20,000,000) for the products sold by Shandong Taibang Biological Products Co., Ltd. (“Shandong Taibang”) and Guizhou Taibang Biological Products Co., Ltd. (“Guizhou Taibang”), respectively. There were no product liability claims as of December 31, 2013.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
	Share-based Payment
	The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period during which an employee is required to provide service in exchange for the award, which generally is the vesting period.
	Long-lived Assets
	Long-lived assets, such as property, plant and equipment, and purchased intangible asset subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company recognized a loss on abandonment and write-off of long-lived assets totaling $6,603,028 for the year ended December 31, 2011 as described in Note 8.
	Net Income per Share
	Basic net income per share of common stock is computed by dividing net income attributable to common stockholders by the weighted average number of common stock outstanding during the year using the two-class method. Under the two-class method, net income is allocated between common stock and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as common stockholders. Diluted net income per share is calculated by dividing net income attributable to common stockholders as adjusted for the effect of dilutive common stock equivalent, if any, by the weighted average number of common stock and dilutive common stock equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive.
	Segment Reporting
	The Company has one operating segment, which is the manufacture and sales of human plasma products. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented.
	Contingencies
	In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

ACCOUNTS_RECEIVABLE

ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
ACCOUNTS RECEIVABLE	'
	NOTE 3 – ACCOUNTS RECEIVABLE
	Accounts receivable at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Accounts receivable	17,730,821	11,621,851
	Less: Allowance for doubtful accounts	-460,689	-415,607
	Total	17,270,132	11,206,244
	The activity in the allowance for doubtful accounts for the years ended December 31, 2013, 2012 and 2011 are as follows:
		For the Years Ended
		December 31, 2013	December 31, 2012	December 31, 2011
		USD	USD	USD
	Beginning balance	415,607	414,092	1,238,640
	Provisions	31,567	-	-
	Recoveries	-	-1,904	-19,611
	Write-offs	-	-	-837,975
	Foreign currency translation adjustment	13,515	3,419	33,038
	Ending Balance	460,689	415,607	414,092

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	NOTE 4 – INVENTORIES
	Inventories at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Raw materials	47,400,578	29,596,746
	Work-in-process	20,720,666	24,524,142
	Finished goods	20,513,611	21,558,285
	Total	88,634,855	75,679,173
	Raw materials mainly comprised of the human blood plasma collected from the Company’s plasma stations. Work-in-process represented the intermediate products in the process of production. Finished goods mainly comprised human albumin and immunoglobulin products. Provisions to write-down the carrying amount of obsolete inventory to its estimated net realizable value amounted to nil, nil and $270,929 for the years ended December 31, 2013, 2012 and 2011, respectively, and were recorded as cost of sales in the consolidated statements of comprehensive income.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Buildings	31,714,173	25,183,496
	Machinery and equipment	36,919,094	29,625,166
	Furniture, fixtures, office equipment and vehicles	8,141,993	6,513,482
	Total property, plant and equipment, gross	76,775,260	61,322,144
	Accumulated depreciation	-25,658,760	-24,356,752
	Total property, plant and equipment, net	51,116,500	36,965,392
	Construction in progress	19,050,642	3,501,404
	Prepayment for property, plant and equipment	2,981,930	10,858,381
	Property, plant and equipment, net	73,149,072	51,325,177
	Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was $6,096,650, $5,792,418 and $4,253,661, respectively. No interest expenses were capitalized into construction in progress for the years ended December 31, 2013, 2012 and 2011.

INTANGIBLE_ASSETS_NET

INTANGIBLE ASSETS, NET	12 Months Ended
	Dec. 31, 2013
Finite-Lived Intangible Assets, Net [Abstract]	'
INTANGIBLE ASSETS, NET	'
	NOTE 6 – INTANGIBLE ASSETS, NET
	Intangible assets at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013
		Weighted
		average		Gross				Net
		amortization		carrying		Accumulated		carrying
		period		amount		amortization		amount
				USD		USD		USD
	Amortizing intangible assets:
	Permits and licenses	10 years		5,144,788		-2,748,704		2,396,084
	GMP certificate	5 years		2,605,253		-2,605,253		-
	Long-term customer-relationship	4 years		7,756,106		-7,756,106		-
	Others			365,754		-176,606		189,148
	Total			15,871,901		-13,286,669		2,585,232
			December 31, 2012
			Weighted
			average		Gross				Net
			amortization		carrying		Accumulated		carrying
			period		amount		amortization		amount
					USD		USD		USD
	Amortizing intangible assets:
	Permits and licenses		10 years		4,987,647		-2,119,622		2,868,025
	GMP certificate		5 years		2,525,679		-1,955,360		570,319
	Long-term customer-relationship		4 years		7,519,206		-7,519,206		-
	Others				214,520		-111,282		103,238
	Total				15,247,052		-11,705,470		3,541,582
	Aggregate amortization expense for amortizing intangible assets was $1,196,279, $3,011,560 and $3,270,131, for the years ended December 31, 2013, 2012 and 2011, respectively. Estimated amortization expenses for the next five years are $516,678 in 2014, $514,884 in 2015, $509,277 in 2016, $474,897 in 2017, and $431,726 in 2018.

DEPOSITS_RELATED_TO_LAND_USE_R

DEPOSITS RELATED TO LAND USE RIGHTS	12 Months Ended
	Dec. 31, 2013
Deposits Related To Land Use Rights [Abstract]	'
DEPOSITS RELATED TO LAND USE RIGHTS	'
	NOTE 7 – DEPOSITS RELATED TO LAND USE RIGHTS
	In 2012, Guizhou Taibang made a refundable payment of RMB83,400,000 (approximately $13,235,580) to the local government in connection with the public bidding for a land use right in Guizhou Province. Given the decrease of the land area to be provided by the local government, RMB13,000,000 (approximately $2,128,100) was refunded by the end of 2013 accordingly. Further, additional RMB10,000,000 (approximately $1,637,000) was refunded in early 2014 by the local government. The remaining deposits will be refunded within one year following the completion of the bidding process.

GOODWILL

GOODWILL	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL	'
	NOTE 8 – GOODWILL
	The changes in the carrying amount of goodwill for the years ended December 31, 2013, 2012 and 2011 were as follows:
		For the Years ended
		December 31,	December 31,	December 31,
		2013	2012	2011
		USD	USD	USD
	Balance as of January 1	-	-	17,778,231
	Addition	-	-	-
	Impairment loss	-	-	-18,160,281
	Foreign currency exchange difference	-	-	382,050
	Balance as of December 31	-	-	-
	On July 15, 2011, the Guizhou Provincial Health Department issued the revised “Plan for Guizhou Provincial Blood Collection Institution Setting (2011-2014)”, which stipulates the number of counties that are permitted to set up plasma collection stations in Guizhou Province is limited to four counties (the “Guizhou Plan”). As a result of the implementation of the Guizhou Plan, the licenses of four plasma collection stations and one inactive plasma collection station with respect to Guizhou Taibang were not renewed upon their expiration on July 31, 2011. Therefore, the Company closed these plasma collection stations on August 1, 2011. Following the closure, the Company revised its earnings guidance for the year of 2011 and experienced incremental decline in its stock price and market capitalization in the third quarter of 2011. Therefore the Company performed goodwill impairment test as of September 30, 2011 to identify if goodwill should be impaired.
	A two step process is used to test for goodwill impairment. The first step is to determine if there is an indication of impairment by comparing the estimated fair value of the reporting unit to its carrying value including existing goodwill. Goodwill is considered impaired if the carrying value of a reporting unit exceeds the estimated fair value. If an indication of impairment exists under the first step, a second step is performed to determine the amount of the impairment. This involves calculating the implied fair value of goodwill by allocating the fair value of the reporting unit to all assets and liabilities other than goodwill and comparing it to the carrying amount of goodwill.
	The fair value of the reporting unit for step one was determined based on the quoted market price of the Company’s common stock. The first step of the impairment test concluded that the carrying value of the Company’s reporting unit exceeded its fair value. As a result, the Company performed the second step of the goodwill impairment test for its reporting unit. The Company determined that the implied fair value of goodwill was nil. Therefore, a goodwill impairment loss of $18,160,281 was recognized for the year ended December 31, 2011.
	As a result of the plasma collection stations closure, the Company also recognized a loss on abandonment of property, plant and equipment of $1,410,379 and loss on the write off of collection permits and licenses totaling $5,192,649 for the year ended December 31, 2011.

RESTRICTED_CASH_AND_DEPOSIT

RESTRICTED CASH AND DEPOSIT	12 Months Ended
	Dec. 31, 2013
Restricted Cash and Investments [Abstract]	'
RESTRICTED CASH AND DEPOSIT	'
	NOTE 9 – RESTRICTED CASH AND DEPOSIT
	On November 1, 2012, Guizhou Taibang entered into an agreement with the Financial Bureau of Huaxi District, Guiyang City. Pursuant to the agreement, the Financial Bureau of Huaxi District provided $2,912,145 (or RMB18,350,000) to Guizhou Taibang to subsidize its technical upgrade in the existing production facilities to comply with a new Good Manufacturing Practice (“GMP”) standard that has taken effect by the end of 2013. The agreement is valid for a three-year period. The usage of this fund is under the supervision of the Financial Bureau of Huaxi District and this fund cannot be used for other purposes. During the year ended December 31, 2013, RMB17,888,952 (approximately $2,928,421) was used in the technical upgrade in respect of the new GMP standard. At December 31, 2013, the balance of restricted cash was RMB461,048 (approximately $75,474).
	On August 7, 2013, the Company made a time deposit of RMB186,000,000 (approximately $30,000,000) with China Merchants Bank Beijing Branch (“CMB BJ Branch”) as a security for an 18-month US$30,000,000 loan lent by China Merchants Bank Co., Ltd., New York Branch (“CMB NY Branch”) (see Note 11).

EQUITY_METHOD_INVESTMENT

EQUITY METHOD INVESTMENT	12 Months Ended
	Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
EQUITY METHOD INVESTMENT	'
	NOTE 10 – EQUITY METHOD INVESTMENT
	The Company’s equity method investment as of December 31, 2013 and 2012 represented 35% equity interest investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitian”).
	In October 2008, Shandong Taibang entered into an equity purchase agreement with one of the equity owners of Huitian (“Seller”) to acquire 35% equity interest in Huitian. In connection with this transaction, in October 2008, Taibang Biological Limited (“Taibang Biological”) entered into an entrust agreement (the “Entrust Agreement”) with Shandong Taibang and the noncontrolling interest holder of Shandong Taibang, pursuant to which, Taibang Biological would pay the cash consideration, including interest, of $6,502,901 (or RMB44,327,887) to the Seller, and would bear the risks and benefits as a 35% equity owner in Huitian. In addition, Taibang Biological would pay Shandong Taibang RMB120,000 (approximately $19,644) per year as compensation for the administrative costs of Shandong Taibang’s holding of the 35% equity interest in Huitian on behalf of Taibang Biological. Such amount paid and received is eliminated upon consolidation. Taibang Biological agreed to indemnify the noncontrolling interest holder of Shandong Taibang for any loss arising from the Entrust Agreement and has pledged the Company’s equity interest in Shandong Taibang as collateral against such loss.
	The excess of carrying amount over the Company’s share of net assets of equity method investees is $2,076,329 and $2,722,915 at December 31, 2013 and 2012, respectively, which comprises fair value adjustments for property, plant and equipment and land use right of $736,707 and $1,424,210 at December 31, 2013 and 2012, respectively, and goodwill of $1,339,622 and $1,298,705 at December 31, 2013 and 2012, respectively. The fair value adjustments are amortized over the remaining useful lives of related assets. The equity method goodwill is not amortized; however, the investment is reviewed for impairment.

BANK_LOANS

BANK LOANS	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
BANK LOANS	'
	NOTE 11 –BANK LOANS
	(a)  Short-term bank loans
	The Company’s bank loans at December 31, 2013 and 2012 consisted of the following:
		Maturity	Annual			December 31,		December 31,
	Loans	date	interest rate			2013		2012
							USD		USD
	Short-term bank loan, unsecured	1-Aug-13		6	%		-		3,174,000
	Short-term bank loan, unsecured	3-Sep-13		6	%		-		3,174,000
	Short-term bank loan, unsecured	3-Sep-13		6	%		-		1,587,000
	Short-term bank loan, unsecured	12-May-14		6	%		4,911,000		-
	Short-term bank loan, unsecured	22-Dec-14		6	%		4,911,000		-
	Total						9,822,000		7,935,000
	Interest expense amounted to $347,602, $446,381 and $705,426 for the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company did not have any revolving line of credit as of December 31, 2013 and 2012.
	(b)  Long-term bank loans
	On August 8, 2013, the Company entered into a credit facility agreement with CMB NY Branch to finance the share repurchase (see Note 17). Pursuant to the facility agreement, CMB NY Branch lends to the Company an 18-month US$30,000,000 loan bearing an interest rate of3-month LIBOR plus 1.6% per annum and a facility fee of 0.7% per annum. The loan is secured by a time deposit of RMB 186,000,000 (approximately $30,448,200) held at CMB BJ Branch.

OTHER_PAYABLES_AND_ACCRUED_EXP

OTHER PAYABLES AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
OTHER PAYABLES AND ACCRUED EXPENSES	'
	NOTE 12 – OTHER PAYABLES AND ACCRUED EXPENSES
	Other payables and accrued expenses at December 31, 2013 and 2012 consisted of the following:
			December 31, 2013		December 31, 2012
			USD		USD
	Payables to potential investors (1)			9,403,649	8,728,368
	Salaries and bonuses payable			8,217,129	6,868,908
	Accruals for selling commission and promotion fee			3,566,693	3,476,215
	Dividends payable to noncontrolling interest			1,411,094	-
	Payables for construction work			4,427,423	347,877
	Other tax payables			2,119,024	2,180,643
	Others			5,707,728	3,821,338
	Total			34,852,740	25,423,349
	-1	The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.
		In 2007, Guizhou Taibang received an aggregate amount of $7,506,408 (or RMB50,960,000) from certain potential strategic investors in connection with their subscription to purchase shares in Guizhou Taibang. The registration of the new investors as Guizhou Taibang’s shareholders and the related increase in registered capital of Guizhou Taibang with the Administration for Industry and Commerce are pending due to shareholders dispute as described in the legal proceeding section (see Note 20). In 2010, the Company refunded $1,699,040 (or RMB11,200,000) to one of the potential investors.

INCOME_TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAX	'
	NOTE 13 – INCOME TAX
	The Company and each of its subsidiaries file separate income tax returns.
	The United States of America
	The Company is incorporated in the State of Delaware in the U.S., and is subject to U.S. federal corporate income tax at gradual rates of up to 35%.
	British Virgin Islands
	Taibang Biological is incorporated in the British Virgin Islands. Under the current laws of the British Virgin Islands (BVI), Taibang Biological is not subject to tax on income or capital gains. In addition, upon payments of dividends by Taibang Biological, no British Virgin Islands withholding tax is imposed.
	Hong Kong
	Taibang Holdings (Hong Kong) Limited (“Taibang Holdings”, formerly known as “Logic Holdings (Hong Kong) Limited”) is incorporated in Hong Kong and is subject to Hong Kong’s profits tax rate of 16.5% for the years ended December 31, 2013, 2012 and 2011. Taibang Holdings did not earn any income that was derived in Hong Kong for the years ended December 31, 2013, 2012 and 2011. The payments of dividends by Hong Kong companies are not subject to any Hong Kong withholding tax.
	PRC
	The PRC’s statutory income tax rate is 25%. The Company’s PRC subsidiaries are subject to income tax at 25% unless otherwise specified.
	On February 12, 2009, Shandong Taibang received the High and New Technology Enterprise certificate from the Shandong provincial government. This certificate entitled Shandong Taibang to pay income taxes at a 15% preferential income tax rate for a period of three years from 2008 to 2010. On October 31, 2011, Shandong Taibang obtained a notice from the Shandong provincial government that the High and New Technology Enterprise qualification has been renewed for an additional three years from 2011 to 2013. Subject to reapplication Shangdong Taibang’s High-Tech Enterprise status will enable it to continue to enjoy the preferential income tax rate.  Management believes that Shandong Taibang meets all the criteria for the reapplication of High-Tech Enterprise status.
	Guizhou Taibang was entitled to the preferential income tax rate of 15% under the 10-year Western Development Tax Concession, which ended in 2010. According to CaiShui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of the PRC, enjoys a preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2020.
	The components of earnings (losses) before income taxes by jurisdictions are as follows:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	PRC, excluding Hong Kong	98,401,673		84,980,477		42,616,865
	U.S.	-7,855,555		-6,314,398		-1,403,437
	BVI	2,116,243		2,538,030		1,645,364
	Hong Kong	-260,996		-68,970		-575,924
	Total	92,401,365		81,135,139		42,282,868
	Income tax expense for the years ended December 31, 2013, 2012 and 2011 represents current income tax expense and deferred tax expense (benefit):
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Current income tax expense	15,427,669		14,035,714		13,494,616
	Deferred tax expense (benefit)	112,632		1,127,433		-2,595,103
		15,540,301		15,163,147		10,899,513
	The effective income tax rate based on income tax expense and earnings before income taxes reported in the consolidated statements of comprehensive income differs from the PRC statutory income tax rate of 25% due to the following:
		For the Years Ended
		December 31,			December 31,		December 31,
		2013			2012		2011
		(in percentage to earnings before income tax expense)
	PRC statutory income tax rate	25	%		25	%	25	%
	Non-taxable income	-			-0.7	%	-2.3	%
	Non-deductible expenses:
	Share-based compensation	0.9	%		1.9	%	3.9	%
	Impairment loss on goodwill	-			-		10.7	%
	Loss on write-off of long-lived assets	-			-		0.8	%
	Others	0.7	%		0.4	%	0.7	%
	Tax rate differential	-1	%		-1.2	%	1.6	%
	Effect of change in tax rate on deferred tax	-			-		-1.8	%
	Effect of PRC preferential tax rate	-12.7	%		-11	%	-18.2	%
	Bonus deduction on research and development	-1.4	%		-1.3	%	-1.2	%
	expenses
	Change in valuation allowance	1.7	%		0.7	%	2	%
	PRC dividend withholding tax	2.8	%		4	%	3.1	%
	Tax effect of equity method investment	0.8	%		0.9	%	1.5	%
	Effective income tax rate	16.8	%		18.7	%	25.8	%
	The PRC tax rate has been used because the majority of the Company’s consolidated pre-tax earnings arise in the PRC.
	As of December 31, 2013 and 2012, significant temporary differences between the tax basis and financial statement basis of assets and liabilities that gave rise to deferred taxes were principally related to the following:
		December 31, 2013		December 31, 2012
		USD		USD
	Deferred tax assets arising from:
	-Accrued expenses	2,065,310		1,841,210
	-Tax loss carryforwards	8,950,323		7,078,822
	Gross deferred tax assets	11,015,633		8,920,032
	Less: valuation allowance	-7,558,590		-5,887,981
	Net deferred tax assets	3,457,043		3,032,051
	Deferred tax liabilities arising from:
	- Intangible assets	-548,651		-498,987
- Property, plant and equipment	-		-198,443
- Equity method investment	-1,391,733		-1,190,841
- Dividend withholding tax	-2,467,760		-1,955,186
Deferred tax liabilities	-4,408,144		-3,843,457
Classification on consolidated balance sheets:
Deferred tax assets – current, net (included in prepayments and other current assets)	2,065,310		1,841,210
Deferred tax liabilities - non-current, net (included in other liabilities)	-3,016,411		-2,652,616
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible and tax loss carryforwards are utilized. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryforwards periods), projected future taxable income, and tax planning strategies in making this assessment.
The deferred tax assets of $8,950,323 for tax loss carry forwards as of December 31, 2013, of which $4,730,841 and $4,219,482 relate to tax loss carryforwards of certain PRC subsidiaries and CBP, respectively. For PRC income tax purposes, certain of the Company's PRC subsidiaries had tax loss carryforwards of $18,923,363, of which $1,153,544, $5,220,932, $7,180,046 and $5,368,841 would expire by 2015, 2016, 2017 and 2018, respectively, if unused. For United States federal income tax purposes, CBP had tax loss carryforwards of approximately $12,410,240, of which $1,268,307, $614,982, $1,113,597, $1,405,718, $2,350,326, $3,382,154, $978,837 and $1,296,319 would expire by 2026, 2027, 2028, 2029, 2030, 2031, 2032 and 2033, respectively, if unused. In view of their cumulative losses positions, management determined it is more likely than not that deferred tax assets of these PRC subsidiaries will not be realized, and therefore full valuation allowances of $4,730,841 and $3,300,089 were provided as of December 31, 2013 and 2012, respectively. For deferred tax assets of CBP, management determined it is more likely than not that some portion of the deferred tax assets of CBP will not be realized, and therefore valuation allowances of $2,827,749 and $2,587,892 were provided as of December 31, 2013 and 2012, respectively. The change in valuation allowance for the years ended December 31, 2013, 2012 and 2011 was an increase of $1,588,875, a decrease of $1,280,005 and an increase of $830,497, respectively. Management believes it is more likely than not that the Company will realize the benefits of the deferred tax assets, net of the valuation allowances, as of December 31, 2013 and December 31, 2012.
According to the prevailing PRC income tax law and relevant regulations, dividends relating to earnings accumulated beginning on January 1, 2008 that are received by non-PRC-resident enterprises from PRC-resident enterprises are subject to withholding tax at 10%, unless reduced by tax treaties or similar arrangement. Dividends relating to undistributed earnings generated prior to January 1, 2008 are exempt from such withholding tax. Further, dividends received by the Company from its overseas subsidiaries are subject to the U.S. federal income tax at 34%, less any qualified foreign tax credits. Based on the dividend policy the Company has provided the deferred tax liabilities of $2,467,760 on undistributed earnings of $25 million, approximately 20% of Shandong Taibang’s total undistributed earnings at December 31, 2013. Due to the Company’s plan and intention of reinvesting its earnings in its PRC business, the Company has not provided for the related deferred tax liabilities on the remaining undistributed earnings of the PRC subsidiaries totaling $162 million as of December 31, 2013.
As of January 1, 2011 and for each of the years ended December 31, 2011, 2012 and 2013, the Company and its subsidiaries did not have any unrecognized tax benefits, and therefore no interest or penalties related to unrecognized tax benefits were accrued. The Company does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months.
The Company and each of its PRC subsidiaries file income tax returns in the United States and the PRC, respectively. The Company is subject to U.S. federal income tax examination by tax authorities for tax years beginning in 2007. According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100,000 (approximately $15,000). In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. The PRC tax returns for the Company’s PRC subsidiaries are open to examination by the PRC tax authorities for the tax years beginning in 2008.

WARRANTS_OPTIONS_AND_NONVESTED

WARRANTS, OPTIONS AND NONVESTED SHARES	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
WARRANTS, OPTIONS AND NONVESTED SHARES	'
	NOTE 14 – WARRANTS, OPTIONS AND NONVESTED SHARES
	Warrants
	In connection with the issuance of convertible notes in 2009, which were fully converted by December 31, 2011, the Company issued warrants to purchase 1,194,268 and 93,750 shares of its common stock to the investors and placement agent, respectively.
	The summary of warrant activities is as follows:
					Weighted			Average
		Warrants			Average			Remaining
		Outstanding			Exercise Price			Contractual Life
		USD
	1-Jan-11		937,500			4.8			1.44
	Granted		-			-			-
	Exercised		-			-			-
	31-Dec-11		937,500			4.8			0.44
	Granted		-			-			-
	Exercised		-937,500			4.8			-
	31-Dec-12		-			-			-
	Granted		-			-			-
	Exercised		-			-			-
	31-Dec-13		-			-			-
	In June 2012, the warrants to purchase 937,500 shares of common stock of the Company were exercised and the Company received proceeds of $4,500,000. There were no warrants outstanding thereafter.
	The fair values of the warrants that were exercised on June 6 and June 4, 2012, and outstanding as of December 31, 2011 were determined based on the Binominal option pricing model, using the following key assumptions:
		June 6, 2012				June 4, 2012				December 31, 2011
	Expected dividend yield		0	%			0	%			0	%
	Risk-free interest rate		0.05	%			0.04	%			0.05	%
	Time to maturity (in years)		-				-				0.43
	Expected volatility		47.4	%			37.3	%			80	%
	Fair value of underlying common shares (per share)	$	9.22			$	8.55			$	10.46
	Change in fair value of derivative liabilities for the years ended December 31, 2011 and 2012 is set forth below:
					Decrease
		Fair value			in fair value			Fair value at			Fair value at		Fair value
		at January			for the year ended			date of warrants			date of notes		at December
		1, 2011			December 31, 2011			exercise			conversion		31, 2011
		USD			USD			USD			USD		USD
	Embedded conversion option in the notes		14,561,661			-6,289,661			-			-8,272,000		-
	Warrants issued to investors		11,095,592			-5,685,173			-			-		5,410,419
	Total		25,657,253			-11,974,834			-			-8,272,000		5,410,419
					Decrease
		Fair value			in fair value			Fair value at			Fair value
		at January			for the year ended			date of warrants			at December
		1, 2012			December 31, 2012			exercise			31, 2012
		USD			USD			USD			USD
	Warrants issued to investors		5,410,419			-1,769,140			-3,641,279			-
	Total		5,410,419			-1,769,140			-3,641,279			-
	Options
	Effective May 9, 2008, the Board of Directors adopted the China Biologic Products, Inc. 2008 Equity Incentive Plan, (“the 2008 Plan”). The 2008 Plan provides for grants of stock options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total of five million shares of the Company’s common stock may be issued pursuant to the 2008 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant date, except that, in the case of an incentive stock option granted to a person who holds more than 10% of the total combined voting power of all classes of the Company’s stock or any of its subsidiaries, the exercise price will be no less than 110% of the fair market value per share on the grant date. No awards may be granted under the 2008 Plan after May 9, 2018, except that any award granted before then may extend beyond that date. All the options to be granted will have 10-year terms.
	For the year ended December 31, 2011, stock options to purchase an aggregate of 175,000 common stock were granted to directors and employees at exercise prices ranging from $5.97 to $17.00 per share with vesting periods of 1 year.
	For the year ended December 31, 2012, stock options to purchase an aggregate of 900,000 common stock were granted to directors and employees at exercise prices ranging from $9.16 to $9.85 per share with vesting periods ranging from 1 year to 4 years.
	For the year ended December 31, 2013, stock options to purchase an aggregate of 33,000 common stock were granted to directors and employees at exercise prices ranging from $4.00 to $12.26 which vested immediately.
	A summary of stock options activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
								Weighted
					Weighted			Average
					Average			Remaining
		Number of			Exercise			Contractual			Aggregate
		Options			Price			Term in years			Intrinsic Value
						USD						USD
	Outstanding as of January 1, 2011		1,906,600			8.5			8.55			15,039,114
	Granted		175,000			15.28
	Exercised		-75,000			4						-635,250
	Forfeited and expired		-12,000			12.26
	Outstanding as of December 31, 2011		1,994,600			9.24			7.71			5,197,076
	Granted		900,000			9.61
	Exercised		-90,990			7.99						-468,322
	Forfeited and expired		-155,001			9.69
	Outstanding as of December 31, 2012		2,648,609			9.39			7.65			18,374,422
Granted		33,000			10.48
Exercised		-648,379			8.32						-10,923,644
Forfeited and expired		-150,854			6.78
Outstanding as of December 31, 2013		1,882,376			9.98			7.2			35,518,897
Vested and expected to vest as of December 31, 2013		1,882,376			9.98			7.2			35,518,897
Exercisable as of December 31, 2013		1,357,376			10.1			6.69			25,450,897
The weighted average option fair value of $8.37 per share or an aggregate of $276,250 on the date of grant during the year ended December 31, 2013, the weighted average option fair value of $7.58 per share or an aggregate of $6,817,649 on the date of grant during the year ended December 31, 2012, and the weighted average option fair value of $8.95 per share or an aggregate of $1,566,250 on the date of grant during the year ended December 31, 2011, were determined based on the Black-Scholes option pricing model using the following weighted average assumptions:
	For the Years Ended
	December 31,				December 31,				December 31,
	2013				2012				2011
Expected volatility		104	%			104	%			69.43	%
Expected dividends yield		0	%			0	%			0	%
Expected term (in years)		5.38				6.01				5
Risk-free interest rate		0.72	%			0.82	%			1.92	%
Fair value of underlying common stock (per share)	$	10.48			$	9.61			$	15.28
The volatility of the Company’s common stock was estimated by management based on the historical volatility of the Company’s common stock. The risk free interest rate was based on Treasury Constant Maturity Rates published by the U.S. Federal Reserve for periods applicable to the estimated term of the options. The expected dividend yield was based on the Company’s current and expected dividend policy.
For the years ended December 31, 2013, 2012 and 2011, the Company recorded stock compensation expense of $3,773,073, $4,335,595 and $4,896,232, respectively, in general and administrative expenses.
As of December 31, 2013, approximately $3,654,022 of stock compensation expense with respect to stock options is to be recognized over weighted average period of approximately 2.22 years.
Nonvested shares
For the years ended December 31, 2012 and 2013, nonvested shares were granted to certain directors and employees (collectively, the “Participant”). Pursuant to the nonvested share grant agreements between the Company and the Participant, the Participant will have all the rights of a stockholder with respect to the nonvested shares. The nonvested shares granted to directors generally vest in one or two years. The nonvested shares granted to employees generally vest in four years.
A summary of nonvested shares activity for the year ended December 31, 2013 is as follow:
	Number of			Grant date weighted
	nonvested shares			average fair value
				USD
Outstanding as of December 31, 2011		-			-
Granted		120,000			9.85
Vested		-			-
Forfeited		-			-
Outstanding as of December 31, 2012		120,000			9.85
Granted		306,500			22.94
Vested		-63,750			9.85
Forfeited		-			-
Outstanding as of December 31, 2013		362,750			20.91
For the year ended December 31, 2013 and 2012, the Company recorded stock compensation expense of $1,277,723 and $209,332 in general and administrative expenses, respectively.
As of December 31, 2013, approximately $6,724,915 of stock compensation expense with respect to nonvested shares is to be recognized over weighted average period of approximately 3.21 years.

STOCKHOLDER_RIGHTS_PLAN

STOCKHOLDER RIGHTS PLAN	12 Months Ended
	Dec. 31, 2013
Stockholder Rights Plan [Abstract]	'
STOCKHOLDER RIGHTS PLAN	'
	NOTE 15 – STOCKHOLDER RIGHTS PLAN
	On November 19, 2012, the Board of Directors adopted a stockholder rights plan (the “Rights Agreement”). Pursuant to the Rights Agreement, the Board of Directors declared a dividend distribution of one right for each share of common stock. Each right entitles the holder to purchase from the Company one one-thousandth of a share of Series A Participating Preferred Stock at an initial exercise price of $60 per share. The Rights Agreement is intended to assure that all of the Company’s stockholders receive fair and equal treatment in the event of any proposed takeover of the Company and to protect stockholders’ interests in the event the Company is confronted with coercive or unfair takeover tactics. As of December 31, 2013, 1,000,000 shares of Series A Participating Preferred Stock were authorized and none was issued or outstanding.
	Rights become exercisable only upon the occurrence of certain events. More specifically, if a person or group acquires 10% or more of the Company (including through derivatives) while the stockholder rights plan remains in place, then the rights will become exercisable by all rights holders (except the acquiring person or group) for shares of the Company’s common stock having a then-current market value of twice the exercise price of a right. However, if a stockholder’s beneficial ownership of the Company’s common stock as of the time of this announcement of the stockholder rights plan and associated dividend declaration is at or above the 10% threshold, that stockholder’s existing ownership percentage would be grandfathered, but the rights would become exercisable if at any time after this announcement the stockholder increases its ownership percentage by 2% or more without the prior approval of the Company’s Board of Directors. In addition, if after a person or group acquires 10% or more of the Company’s outstanding common stock, the Company merges into another company, an acquiring entity merges into the Company or the Company sells or transfers more than 50% of its assets, cash flow or earning power, then each right will entitle its holder to purchase, for the exercise price, a number of shares of common stock of the person engaging in the transaction having a then-current market value of twice the exercise price. The acquiring person will not be entitled to exercise these rights. The Board of Directors may redeem the rights for $0.001 per right at any time before an event that causes the rights to become exercisable. If not redeemed, the rights will expire on November 18, 2014.

STATUTORY_RESERVES

STATUTORY RESERVES	12 Months Ended
	Dec. 31, 2013
Statutory Accounting Practices [Abstract]	'
STATUTORY RESERVES	'
	NOTE 16 – STATUTORY RESERVES
	The Company’s PRC subsidiaries are required to allocate at least 10% of its after tax profits as determined under generally accepted accounting principal in the PRC to its statutory surplus reserve until the reserve balance reaches 50% of respective registered capital. The accumulated balance of the statutory reserve as of December 31, 2013 and 2012 was $30,796,531 and $30,772,993, respectively.

SHARE_REPURCHASE

SHARE REPURCHASE	12 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
SHARE REPURCHASE	'
	NOTE 17– SHARE REPURCHASE
	On August 2, 2013, the Company entered into an agreement with one of its individual shareholders, pursuant to which the Company repurchased 1,479,704 shares of common stock for a consideration of US$29,594,080. The transaction was completed on August 8, 2013.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 18 – FAIR VALUE MEASUREMENTS
	Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates:
	• Short-term financial instruments (including cash, time deposit, accounts receivable, other receivables, short-term bank loans, accounts payable, other payables and accrued expenses, and amount due to related parties) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments.
	• Restricted cash and deposit – The carrying amounts of the restricted cash and deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.
	• Long-term bank loan – fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company’s bankers for similar debt instruments of comparable maturities.

SALES

SALES	12 Months Ended
	Dec. 31, 2013
Sales [Abstract]	'
SALES	'
	NOTE 19 – SALES
	The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the years ended December 31, 2013, 2012 and 2011 are as follows:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Human Albumin		89,671,619		82,450,825		83,433,691
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection		77,341,616		72,005,196		49,482,514
	Other Immunoglobulin products		19,682,927		19,377,603		16,669,069
	Placenta Polypeptide		12,150,539		10,088,754		1,935,428
	Others		4,510,155		891,117		1,571,587
	Total		203,356,856		184,813,495		153,092,289

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 20 – COMMITMENTS AND CONTINGENCIES
	Capital commitments
	At December 31, 2013, commitments outstanding for the purchase of property, plant and equipment approximated $4,619,975.
	Legal proceedings
	Dispute among Guizhou Taibang Shareholders over Raising Additional Capital
	In May 2007, a 91% majority of Guizhou Taibang’s shareholders approved a plan to raise additional capital from private strategic investors through the issuance of an additional 20,000,000 shares of Guizhou Taibang at RMB2.80 per share. The plan required all existing Guizhou Taibang shareholders to waive their rights of first refusal to subscribe for the additional shares. The remaining 9% minority shareholder of Guizhou Taibang’s shares, Guizhou Jie’an Company (“Jie’an”), did not support the plan and did not waive its right of first refusal. In May 2007, the majority shareholders caused Guizhou Taibang to sign an Equity Purchase Agreement with certain investors, pursuant to which the investors agreed to invest an aggregate of $7,475,832 (or RMB50,960,000) in exchange for 18,200,000 shares, or 21.4%, of Guizhou Taibang’s equity interests. At the same time, Jie’an also subscribed for 1,800,000 shares, representing its pro rata share of the 20,000,000 shares being offered. The proceeds from all parties were received by Guizhou Taibang in accordance with the agreement.
	In June 2007, Jie’an brought suit in the High Court of Guizhou province, China, against Guizhou Taibang and the three other original shareholders of Guizhou Taibang, alleging the illegality of the Equity Purchase Agreement. In its complaint, Jie’an claimed that it had a right to acquire the 18,200,000 shares offered to the strategic investors under the Equity Purchase Agreement. In September 2008, the Guizhou High Court ruled against Jie’an and sustained the Equity Purchase Agreement. In November 2008, Jie’an appealed the Guizhou High Court judgment to the People’s Supreme Court in Beijing. In May 2009, the People’s Supreme Court sustained the original ruling and denied the rights of first refusal of Jie’an over the 18,200,000 shares.
	During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital injection with the local Administration for Industry and Commerce, or AIC, pursuant to the Equity Purchase Agreement, and such request was approved by the majority shareholders of Guizhou Taibang in a shareholders meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request, pending the outcome of the ongoing litigation. In March 2012, the Company received a subpoena that Jie’an brought suit in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging Guizhou Taibang’s withholding of its request. Jie’an requested that Guizhou Taibang register its 1.8 million shares of capital injection, pay dividends associated with these shares, as well as the related interest and penalty from May 2007 to December 2011 amounting to $3,967,500 (or RMB25,000,000) in aggregate, and return the over-paid subscription of $228,528 (or RMB1,440,000), as well as the interest and penalty, amounting to $1,587,000 (or RMB10,000,000) in aggregate. The People’s Court of Huaxi District, Guizhou Province, has accepted Jie’an’s suit. In May 2012, Guizhou Taibang was informed by the court that the case was postponed upon the request from Jie’an.
	In December 2013, Jie’an brought suit again in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, again alleging Guizhou Taibang’s withholding of its request. The People’s Court of Huaxi District, Guizhou  Province, has accepted Jie’an’s suit and heard the case on February 26, 2014. The Company is awaiting the judgment as of the date of this report. If the Company decides to ratify the approval or the case is ruled in Jie’an’s favor, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an may be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an’s capital contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail. As of December 31, 2013, the Company had recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $825,048) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $235,728) for the over-paid subscription and RMB2,937,473 (approximately $480,864) for the accrued interest.
	As a result of this dispute, the strategic investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have not been registered with the local AIC. In January 2010, the strategic investors brought suit in the High Court of Guizhou Province against Guizhou Taibang alleging Guizhou Taibang’s failure to register their equity interest in Guizhou Taibang with the local AIC and requesting the distribution of their share of Guizhou Taibang’s dividends declared since 2007. Dalin was also joined as a co-defendant as it is the majority shareholder and exercises control over Guizhou Taibang’s day-to-day operations.
	In October, 2010, the High Court of Guizhou ruled in favor of the Company and denied the strategic investors’ right as shareholders of Guizhou Taibang, as well as their entitlement to the dividends. In light of the Guizhou ruling, the Company returned the proceeds of $1,699,040 (or RMB11,200,000) to one of the strategic investors in November 2010. In October 2010, the other strategic investors appealed to the PRC Supreme Court in Beijing on the ruling of the High Court of Guizhou. The PRC Supreme Court overruled the decision of the High Court of Guizhou and remanded the case to the High Court of Guizhou for retrial. In January 2012, the strategic investors re-filed their case to the High Court of Guizhou requesting, in addition to the share distribution, the distribution of dividends and interest in the amount of RMB18,349,345 (approximately $2,990,943) and RMB2,847,000 (approximately $464,061), respectively. In December 2012, the High Court of Guizhou affirmed the judgment against the strategic investors. In January 2013, the strategic investors appealed to the PRC Supreme Court on the ruling again and the appeal was accepted.
	In September 2013, the PRC Supreme Court made the final judgment against the strategic investors and denied the strategic investors’ right as shareholders of Guizhou Taibang and their claim for the related dividend distribution. In November 2013, the strategic investors appealed to the PRC Supreme Court on the judgement and was rejected by the PRC Supreme Court on January 17, 2014. As of December 31, 2013, Guizhou Taibang has made provision for the strategic investors’ initial fund along with RMB17,174,807 (approximately $2,811,516) in accrued interest, and RMB509,600 (approximately $83,422) for the 1% penalty imposed by the agreement for any breach in the event that Guizhou Taibang is required to return their original investment amount to the strategic investors.
	In April 2013, the Company countersued the strategic investors in the Intermediate Court of Guiyang City alleging their breach of the Security Law in the PRC and requested a consideration of $6,064,800 (or RMB38,000,000) for the related expenses and losses, and Guizhou Intermediate Court accepted the case. The Company is awaiting the hearing of the above case as of the date of this report.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 21 – RELATED PARTY TRANSACTIONS
	The material related party transactions undertaken by the Company with related parties for the years ended December 31, 2013, 2012 and 2011 are presented as follows:
			For the Years Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
			USD			USD			USD
	Sales of products to related parties(1)			-			-			243,563
	Commission expenses with related parties(1)			3,620,335			3,591,836			747,372
	The material related party balances at December 31, 2013 and 2012 are presented as follows:
	Liabilities		Purpose		December 31, 2013			December 31, 2012
					USD			USD
	Other payable – a related party(1)		Commission			351,955			339,272
	Other payable – a related party(2)		Loan			2,383,472			2,311,044
	Other payable – a related party(3)		Contribution			2,929,903			-
	Other payable – related parties(4)		Contribution			1,541,640			1,431,308
	Total other payable – related parties					7,206,970			4,081,624
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. As of December 31, 2013 and 2012, Guizhou Taibang accrued commission payable of $351,955 and $339,272 for service rendered by Guizhou Eakan. The commission expense for service rendered by Guizhou Eakan amounted to $3,620,335, $3,591,836, and $747,372 for the years ended December 31, 2013, 2012 and 2011, respectively.
			Prior to the signing of the agency contract with Guizhou Eakan, Guizhou Taibang provided processing services to Guizhou Eakan. Guizhou Taibang’s total income from processing services to Guizhou Eakan amounted to nil, nil and $243,563 for the years ended December 31, 2013, 2012 and 2011, respectively.
		-2	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,383,472 and $2,311,044 as of December 31, 2013 and 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
		-3	In December 2013, Guizhou Taibang received a contribution of $2,929,903 from Guizhou Eakan Investing Corp. pending for the registration with the local AIC.
		-4	Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,541,640 and $1,431,308 as of December 31, 2013 and 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 20), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $825,048) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $235,728) for the over-paid subscription and RMB2,937,473 (approximately $480,864) for the accrued interest and penalty as of December 31, 2013.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	12 Months Ended
	Dec. 31, 2013
Net Income Loss Per Share Disclosure [Abstract]	'
NET INCOME PER SHARE	'
	NOTE 22 - NET INCOME PER SHARE
	The following table sets forth the computation of basic and diluted net income per share of common stock for the periods indicated:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Net income attributable to China Biologic Products, Inc.		54,601,551		45,222,189		18,181,710
	Earnings allocated to participating nonvested shares		-456,261		-69,624		-
	Net income allocated to common stockholders used in computing		54,145,290		45,152,565		18,181,710
	basic net income per common stock
	Interest on the notes		-		-		3,582,648
	Change in fair value of embedded conversion option in the notes		-		-		-6,289,661
	Change in fair value of warrants issued to investors and placement		-		-1,769,140		-5,685,173
	agent
	Net income used in diluted net income per common stock		54,145,290		43,383,425		9,789,524
	Weighted average shares used in computing basic net income per		26,410,819		26,153,540		25,028,796
	common stock
	Diluted effect of the notes		-		-		515,068
	Diluted effect of warrants issued to investors		-		212,792		551,686
	Diluted effect of stock option		1,161,292		473,391		559,112
	Weighted average shares used in computing diluted net income per		27,572,111		26,839,723		26,654,662
	common stock
	Net income per common stock – basic		2.05		1.73		0.73
	Net income per common stock – diluted		1.96		1.62		0.37
	During the year ended December 31, 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock. Further, rights issued pursuant to the stockholder rights plan (see Note 15) were excluded from the calculation of diluted net income per common stock since they were antidilutive.
	During the year ended December 31, 2012, 1,938,009 options with an average exercise price of $11.34, and rights issued pursuant to the stockholder rights plan, were excluded from the calculation of diluted net income per common stock since they were antidilutive.
	During the year ended December 31, 2011, 1,164,000 options with an average exercise price of $12.84 were excluded from the calculation of diluted net income per share of common stock since they were antidilutive.

CHINA_BIOLOGIC_PRODUCTS_INC_PA

CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)	'
	NOTE 23 – CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)
	The following represents condensed unconsolidated financial information of the Parent Company only:
	Condensed Balance Sheets:
		December 31, 2013		December 31, 2012
		USD		USD
	Cash		679,022		76,101
	Prepayments and prepaid expenses		87,548		95,486
	Property, plant and equipment, net		544		2,575
	Investment in and amounts due from subsidiaries		270,595,266		198,689,734
	Total Assets		271,362,380		198,863,896
	Other payables and accrued expenses		3,670,817		3,394,180
	Long-term loan		30,000,000		-
	Total Liabilities		33,670,817		3,394,180
	Total Equity		237,691,563		195,469,716
	Total Liabilities and Equity		271,362,380		198,863,896
	Condensed Statements of Comprehensive Income:
		For the Years Ended
		December 31, 2013		December 31, 2012		December 31, 2011
		USD		USD		USD
	Equity in income of subsidiaries		62,457,106		51,063,576		19,848,119
	General and administrative expenses		-7,460,763		-8,048,993		-9,669,494
	Other expenses, net		-394,792		-34,543		-3,708,776
	Change in fair value of derivative liabilities		-		1,769,140		11,974,834
	Earnings before income tax expense		54,601,551		44,749,180		18,444,683
	Income tax benefit (expense)		-		473,009		-262,973
	Net Income		54,601,551		45,222,189		18,181,710
	Condensed Statements of Cash Flows:
		For the Years Ended
		December 31, 2013		December 31, 2012		December 31, 2011
		USD		USD		USD
	Net cash provided by (used in) operating activities		197,001		-160,272		-165,551
	Net cash used in investing activities		-		-		-1,970
	Net cash provided by (used in) financing activities		405,920		-		300,000
	Net increase (decrease) in cash		602,921		-160,272		132,479
	Cash at beginning of year		76,101		236,373		103,894
	Cash at end of year		679,022		76,101		236,373

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENT	'
	NOTE 24 – SUBSEQUENT EVENT
	On January 27, 2014, the Company entered into a redemption agreement with one of its individual shareholders, pursuant to which the Company would repurchase 2,500,000 shares of common stock for a consideration of $70,000,000. The transaction was completed on February 28, 2014.
	To finance this share repurchase, the Company entered into a credit facility agreement with CMB NY Branch on February 25, 2014. Pursuant to the facility agreement, CMB NY Branch lent to the Company a 24-month US$40,000,000 loan and an 18-month US$30,000,000 loan, secured by time deposits of RMB246,500,000 (approximately $40,352,050) and RMB194,600,000 (approximately $31,856,020), respectively. Both loans bear an interest rate of 3-month LIBOR plus 1.3% per annum and a facility fee of 1.2% per annum.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation and Basis of Presentation	'
	Principles of Consolidation and Basis of Presentation
	The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation. The Company has no involvement with variable interest entities. The Company accounts for investments over which it has significant influence but not a controlling financial interest using the equity method of accounting.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of fixed assets; the allowance for doubtful accounts; the fair value determinations of financial and equity instruments and the valuation of share-based compensation, assets acquired and liabilities assumed in a business combination, deferred tax assets and inventories; the recoverability of goodwill, intangible asset, land use right and property, plant and equipment; and reserves for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions.
Foreign Currency Translation	'
	Foreign Currency Translation
	The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income.
Revenue Recognition	'
	Revenue Recognition
	Revenue represents the invoiced value of products sold, net of value added taxes (VAT).
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred and the customer takes ownership and assumes risk of loss, the sales price is fixed or determinable and collection of the relevant receivable is probable. The Company mainly sells human albumin and human immunoglobulin to hospitals, inoculation centers and pharmaceutical distributors. For all sales, the Company requires a signed contract or purchase order, which specify pricing, quantity and product specifications. Delivery of the product occurs when the customer receives the product, which is when the risks and rewards of ownership have been transferred. Delivery is evidenced by signed customer acknowledgement. The Company’s sales agreements do not provide the customer the right of return, unless the product is defective in which case the Company allows for an exchange of product or return. For the periods presented, defective product returns were immaterial.
Fair Value Measurements	'
	Fair Value Measurements
	The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
	•        Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date.
	•        Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
	•        Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
	The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	See Note 18 to the Consolidated Financial Statements.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. Cash and cash equivalents include $74,352,540 and $20,631,000 of certificates of deposit with an initial term of three months or less at December 31, 2013 and 2012.
	As of December 31, 2013 and 2012, the Company maintained cash at banks in the following locations:
			December 31, 2013	December 31, 2012
			USD	USD
	PRC, excluding Hong Kong		143,047,540	129,213,360
	U.S.		679,022	76,101
	Total		143,726,562	129,289,461
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. Cost of work in progress and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost. Repair and maintenance costs are expensed as incurred.
	Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Estimated useful lives of the assets are as follows:
	Buildings	30 years
	Machinery and equipment	10 years
	Furniture, fixtures, office equipment and vehicles	5-10 years
Equity Method Investment	'
	Equity Method Investment
	Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20% and 50%, and other factors, such as representation on the board of directors and participation in policy-making processes, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the Company’s share of the investee’s results of operations is included in other income (expenses) in the Company’s consolidated statements of comprehensive income. Deferred taxes are provided for the difference between the book and tax basis of the investment. The Company recognizes a loss if it is determined that other than temporary decline in the value of the investment exists. The process of assessing and determining whether an impairment on a particular equity investment is other than temporary requires a significant amount of judgment. To determine whether an impairment is other-than-temporary, management considers whether the Company has the ability and intent to hold the investment until recovery and whether evidence indicating the carrying value of the investment is recoverable outweighs evidence to the contrary. No impairment loss was recognized by the Company for the years ended December 31, 2013, 2012 and 2011.
Intangible Assets	'
	Intangible Assets
	Intangible assets are stated at cost less accumulated amortization. Amortization expense is recognized on the straight-line basis over the assets’ estimated useful life, as the pattern in which the economic benefits of the intangible assets are used up cannot be reliably determined. The estimated useful life is the period over which the intangible asset is expected to contribute directly or indirectly to the future cash flows of the Company. The Company has no intangible assets with indefinite useful lives. The estimate useful lives of intangible assets are as follows:
	Permits and licenses	10 years
	GMP Certificate	5 years
	Long-term customer-relationship	4 years
Land Use Rights	'
	Land Use Rights
	Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 to 50 years.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2013, 2012 and 2011 were $4,223,165, $3,032,719 and $3,978,233, respectively. These expenses include the costs of the Company’s internal research and development activities.
Product Liability	'
	Product Liability
	The Company’s products are covered by two separate product liability insurances each with coverages of approximately $3,274,000 (or RMB20,000,000) for the products sold by Shandong Taibang Biological Products Co., Ltd. (“Shandong Taibang”) and Guizhou Taibang Biological Products Co., Ltd. (“Guizhou Taibang”), respectively. There were no product liability claims as of December 31, 2013.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
Share-based Payment	'
	Share-based Payment
	The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period during which an employee is required to provide service in exchange for the award, which generally is the vesting period.
Long-lived Assets	'
	Long-lived Assets
	Long-lived assets, such as property, plant and equipment, and purchased intangible asset subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company recognized a loss on abandonment and write-off of long-lived assets totaling $6,603,028 for the year ended December 31, 2011 as described in Note 8.
Net Income per Share	'
	Net Income per Share
	Basic net income per share of common stock is computed by dividing net income attributable to common stockholders by the weighted average number of common stock outstanding during the year using the two-class method. Under the two-class method, net income is allocated between common stock and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as common stockholders. Diluted net income per share is calculated by dividing net income attributable to common stockholders as adjusted for the effect of dilutive common stock equivalent, if any, by the weighted average number of common stock and dilutive common stock equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive.
Segment Reporting	'
	Segment Reporting
	The Company has one operating segment, which is the manufacture and sales of human plasma products. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented.
Contingencies	'
	Contingencies
	In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of cash at banks	'
	As of December 31, 2013 and 2012, the Company maintained cash at banks in the following locations:
			December 31, 2013	December 31, 2012
			USD	USD
	PRC, excluding Hong Kong		143,047,540	129,213,360
	U.S.		679,022	76,101
	Total		143,726,562	129,289,461
Schedule of Estimated useful lives of the assets	'
	Estimated useful lives of the assets are as follows:
	Buildings	30 years
	Machinery and equipment	10 years
	Furniture, fixtures, office equipment and vehicles	5-10 years
Schedule of estimate useful lives of intangible assets	'
	The estimate useful lives of intangible assets are as follows:
	Permits and licenses	10 years
	GMP Certificate	5 years
	Long-term customer-relationship	4 years

ACCOUNTS_RECEIVABLE_Tables

ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
SCHEDULE OF ACCOUNTS RECEIVABLE	'
	Accounts receivable at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Accounts receivable	17,730,821	11,621,851
	Less: Allowance for doubtful accounts	-460,689	-415,607
	Total	17,270,132	11,206,244
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	'
	The activity in the allowance for doubtful accounts for the years ended December 31, 2013, 2012 and 2011 are as follows:
		For the Years Ended
		December 31, 2013	December 31, 2012	December 31, 2011
		USD	USD	USD
	Beginning balance	415,607	414,092	1,238,640
	Provisions	31,567	-	-
	Recoveries	-	-1,904	-19,611
	Write-offs	-	-	-837,975
	Foreign currency translation adjustment	13,515	3,419	33,038
	Ending Balance	460,689	415,607	414,092

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
SCHEDULE OF INVENTORIES	'
	Inventories at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Raw materials	47,400,578	29,596,746
	Work-in-process	20,720,666	24,524,142
	Finished goods	20,513,611	21,558,285
	Total	88,634,855	75,679,173

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	'
	Property, plant and equipment at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013	December 31, 2012
		USD	USD
	Buildings	31,714,173	25,183,496
	Machinery and equipment	36,919,094	29,625,166
	Furniture, fixtures, office equipment and vehicles	8,141,993	6,513,482
	Total property, plant and equipment, gross	76,775,260	61,322,144
	Accumulated depreciation	-25,658,760	-24,356,752
	Total property, plant and equipment, net	51,116,500	36,965,392
	Construction in progress	19,050,642	3,501,404
	Prepayment for property, plant and equipment	2,981,930	10,858,381
	Property, plant and equipment, net	73,149,072	51,325,177

INTANGIBLE_ASSETS_NET_Tables

INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Intangible Assets Disclosure [Abstract]	'
SCHEDULE OF INTANGIBLE ASSETS	'
	Intangible assets at December 31, 2013 and 2012 consisted of the following:
		December 31, 2013
		Weighted
		average		Gross				Net
		amortization		carrying		Accumulated		carrying
		period		amount		amortization		amount
				USD		USD		USD
	Amortizing intangible assets:
	Permits and licenses	10 years		5,144,788		-2,748,704		2,396,084
	GMP certificate	5 years		2,605,253		-2,605,253		-
	Long-term customer-relationship	4 years		7,756,106		-7,756,106		-
	Others			365,754		-176,606		189,148
	Total			15,871,901		-13,286,669		2,585,232
			December 31, 2012
			Weighted
			average		Gross				Net
			amortization		carrying		Accumulated		carrying
			period		amount		amortization		amount
					USD		USD		USD
	Amortizing intangible assets:
	Permits and licenses		10 years		4,987,647		-2,119,622		2,868,025
	GMP certificate		5 years		2,525,679		-1,955,360		570,319
	Long-term customer-relationship		4 years		7,519,206		-7,519,206		-
	Others				214,520		-111,282		103,238
	Total				15,247,052		-11,705,470		3,541,582

GOODWILL_Tables

GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
SCHEDULE OF GOODWILL	'
	The changes in the carrying amount of goodwill for the years ended December 31, 2013, 2012 and 2011 were as follows:
		For the Years ended
		December 31,	December 31,	December 31,
		2013	2012	2011
		USD	USD	USD
	Balance as of January 1	-	-	17,778,231
	Addition	-	-	-
	Impairment loss	-	-	-18,160,281
	Foreign currency exchange difference	-	-	382,050
	Balance as of December 31	-	-	-

BANK_LOANS_Tables

BANK LOANS (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
SCHEDULE OF SHORT-TERM BANK LOANS	'
	The Company’s bank loans at December 31, 2013 and 2012 consisted of the following:
		Maturity	Annual			December 31,		December 31,
	Loans	date	interest rate			2013		2012
							USD		USD
	Short-term bank loan, unsecured	1-Aug-13		6	%		-		3,174,000
	Short-term bank loan, unsecured	3-Sep-13		6	%		-		3,174,000
	Short-term bank loan, unsecured	3-Sep-13		6	%		-		1,587,000
	Short-term bank loan, unsecured	12-May-14		6	%		4,911,000		-
	Short-term bank loan, unsecured	22-Dec-14		6	%		4,911,000		-
	Total						9,822,000		7,935,000

OTHER_PAYABLES_AND_ACCRUED_EXP1

OTHER PAYABLES AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES	'
	Other payables and accrued expenses at December 31, 2013 and 2012 consisted of the following:
			December 31, 2013		December 31, 2012
			USD		USD
	Payables to potential investors (1)			9,403,649	8,728,368
	Salaries and bonuses payable			8,217,129	6,868,908
	Accruals for selling commission and promotion fee			3,566,693	3,476,215
	Dividends payable to noncontrolling interest			1,411,094	-
	Payables for construction work			4,427,423	347,877
	Other tax payables			2,119,024	2,180,643
	Others			5,707,728	3,821,338
	Total			34,852,740	25,423,349
	-1	The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.

INCOME_TAX_Tables

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS	'
	The components of earnings (losses) before income taxes by jurisdictions are as follows:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	PRC, excluding Hong Kong	98,401,673		84,980,477		42,616,865
	U.S.	-7,855,555		-6,314,398		-1,403,437
	BVI	2,116,243		2,538,030		1,645,364
	Hong Kong	-260,996		-68,970		-575,924
	Total	92,401,365		81,135,139		42,282,868
SCHEDULE OF INCOME TAX EXPENSE	'
	Income tax expense for the years ended December 31, 2013, 2012 and 2011 represents current income tax expense and deferred tax expense (benefit):
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Current income tax expense	15,427,669		14,035,714		13,494,616
	Deferred tax expense (benefit)	112,632		1,127,433		-2,595,103
		15,540,301		15,163,147		10,899,513
SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE	'
	The effective income tax rate based on income tax expense and earnings before income taxes reported in the consolidated statements of comprehensive income differs from the PRC statutory income tax rate of 25% due to the following:
		For the Years Ended
		December 31,			December 31,		December 31,
		2013			2012		2011
		(in percentage to earnings before income tax expense)
	PRC statutory income tax rate	25	%		25	%	25	%
	Non-taxable income	-			-0.7	%	-2.3	%
	Non-deductible expenses:
	Share-based compensation	0.9	%		1.9	%	3.9	%
	Impairment loss on goodwill	-			-		10.7	%
	Loss on write-off of long-lived assets	-			-		0.8	%
	Others	0.7	%		0.4	%	0.7	%
	Tax rate differential	-1	%		-1.2	%	1.6	%
	Effect of change in tax rate on deferred tax	-			-		-1.8	%
	Effect of PRC preferential tax rate	-12.7	%		-11	%	-18.2	%
	Bonus deduction on research and development	-1.4	%		-1.3	%	-1.2	%
	expenses
	Change in valuation allowance	1.7	%		0.7	%	2	%
	PRC dividend withholding tax	2.8	%		4	%	3.1	%
	Tax effect of equity method investment	0.8	%		0.9	%	1.5	%
	Effective income tax rate	16.8	%		18.7	%	25.8	%
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	'
	As of December 31, 2013 and 2012, significant temporary differences between the tax basis and financial statement basis of assets and liabilities that gave rise to deferred taxes were principally related to the following:
		December 31, 2013		December 31, 2012
		USD		USD
	Deferred tax assets arising from:
	-Accrued expenses	2,065,310		1,841,210
	-Tax loss carryforwards	8,950,323		7,078,822
	Gross deferred tax assets	11,015,633		8,920,032
	Less: valuation allowance	-7,558,590		-5,887,981
	Net deferred tax assets	3,457,043		3,032,051
	Deferred tax liabilities arising from:
	- Intangible assets	-548,651		-498,987
	- Property, plant and equipment	-		-198,443
	- Equity method investment	-1,391,733		-1,190,841
	- Dividend withholding tax	-2,467,760		-1,955,186
	Deferred tax liabilities	-4,408,144		-3,843,457
	Classification on consolidated balance sheets:
	Deferred tax assets – current, net (included in prepayments and other current assets)	2,065,310		1,841,210
	Deferred tax liabilities - non-current, net (included in other liabilities)	-3,016,411		-2,652,616

WARRANTS_OPTIONS_AND_NONVESTED1

WARRANTS, OPTIONS AND NONVESTED SHARES (Tables)	12 Months Ended
	Dec. 31, 2013
Options and Nonvested Shares [Abstract]	'
SCHEDULE OF WARRANT ACTIVITIES	'
	The summary of warrant activities is as follows:
					Weighted			Average
		Warrants			Average			Remaining
		Outstanding			Exercise Price			Contractual Life
		USD
	1-Jan-11		937,500			4.8			1.44
	Granted		-			-			-
	Exercised		-			-			-
	31-Dec-11		937,500			4.8			0.44
	Granted		-			-			-
	Exercised		-937,500			4.8			-
	31-Dec-12		-			-			-
	Granted		-			-			-
	Exercised		-			-			-
	31-Dec-13		-			-			-
SCHEDULE OF WARRANTS VALUATION	'
	The fair values of the warrants that were exercised on June 6 and June 4, 2012, and outstanding as of December 31, 2011 were determined based on the Binominal option pricing model, using the following key assumptions:
		June 6, 2012				June 4, 2012				December 31, 2011
	Expected dividend yield		0	%			0	%			0	%
	Risk-free interest rate		0.05	%			0.04	%			0.05	%
	Time to maturity (in years)		-				-				0.43
	Expected volatility		47.4	%			37.3	%			80	%
	Fair value of underlying common shares (per share)	$	9.22			$	8.55			$	10.46
SCHEDULE OF CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	'
	Change in fair value of derivative liabilities for the years ended December 31, 2011 and 2012 is set forth below:
					Decrease
		Fair value			in fair value			Fair value at			Fair value at		Fair value
		at January			for the year ended			date of warrants			date of notes		at December
		1, 2011			December 31, 2011			exercise			conversion		31, 2011
		USD			USD			USD			USD		USD
	Embedded conversion option in the notes		14,561,661			-6,289,661			-			-8,272,000		-
	Warrants issued to investors		11,095,592			-5,685,173			-			-		5,410,419
	Total		25,657,253			-11,974,834			-			-8,272,000		5,410,419
					Decrease
		Fair value			in fair value			Fair value at			Fair value
		at January			for the year ended			date of warrants			at December
		1, 2012			December 31, 2012			exercise			31, 2012
		USD			USD			USD			USD
	Warrants issued to investors		5,410,419			-1,769,140			-3,641,279			-
	Total		5,410,419			-1,769,140			-3,641,279			-
SCHEDULE OF STOCK OPTIONS ACTIVITY	'
	A summary of stock options activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
								Weighted
					Weighted			Average
					Average			Remaining
		Number of			Exercise			Contractual			Aggregate
		Options			Price			Term in years			Intrinsic Value
						USD						USD
	Outstanding as of January 1, 2011		1,906,600			8.5			8.55			15,039,114
	Granted		175,000			15.28
	Exercised		-75,000			4						-635,250
	Forfeited and expired		-12,000			12.26
	Outstanding as of December 31, 2011		1,994,600			9.24			7.71			5,197,076
	Granted		900,000			9.61
	Exercised		-90,990			7.99						-468,322
	Forfeited and expired		-155,001			9.69
	Outstanding as of December 31, 2012		2,648,609			9.39			7.65			18,374,422
	Granted		33,000			10.48
	Exercised		-648,379			8.32						-10,923,644
	Forfeited and expired		-150,854			6.78
	Outstanding as of December 31, 2013		1,882,376			9.98			7.2			35,518,897
	Vested and expected to vest as of December 31, 2013		1,882,376			9.98			7.2			35,518,897
	Exercisable as of December 31, 2013		1,357,376			10.1			6.69			25,450,897
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTION	'
		For the Years Ended
		December 31,				December 31,				December 31,
		2013				2012				2011
	Expected volatility		104	%			104	%			69.43	%
	Expected dividends yield		0	%			0	%			0	%
	Expected term (in years)		5.38				6.01				5
	Risk-free interest rate		0.72	%			0.82	%			1.92	%
	Fair value of underlying common stock (per share)	$	10.48			$	9.61			$	15.28
SCHEDULE OF NONVESTED SHARES ACTIVITY	'
	A summary of nonvested shares activity for the year ended December 31, 2013 is as follow:
		Number of			Grant date weighted
		nonvested shares			average fair value
					USD
	Outstanding as of December 31, 2011		-			-
	Granted		120,000			9.85
	Vested		-			-
	Forfeited		-			-
	Outstanding as of December 31, 2012		120,000			9.85
	Granted		306,500			22.94
	Vested		-63,750			9.85
	Forfeited		-			-
	Outstanding as of December 31, 2013		362,750			20.91

SALES_Tables

SALES (Tables)	12 Months Ended
	Dec. 31, 2013
Sales Disclosure [Abstract]	'
SCHEDULE OF SALES BY PRODUCT TYPE	'
	The Company’s sales by significant types of product for the years ended December 31, 2013, 2012 and 2011 are as follows:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Human Albumin		89,671,619		82,450,825		83,433,691
	Immunoglobulin products:
	Human Immunoglobulin for Intravenous Injection		77,341,616		72,005,196		49,482,514
	Other Immunoglobulin products		19,682,927		19,377,603		16,669,069
	Placenta Polypeptide		12,150,539		10,088,754		1,935,428
	Others		4,510,155		891,117		1,571,587
	Total		203,356,856		184,813,495		153,092,289

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
SCHEDULE OF RELATED PARTY TRANSACTION	'
	The material related party transactions undertaken by the Company with related parties for the years ended December 31, 2013, 2012 and 2011 are presented as follows:
			For the Years Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
			USD			USD			USD
	Sales of products to related parties(1)			-			-			243,563
	Commission expenses with related parties(1)			3,620,335			3,591,836			747,372
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. As of December 31, 2013 and 2012, Guizhou Taibang accrued commission payable of $351,955 and $339,272 for service rendered by Guizhou Eakan. The commission expense for service rendered by Guizhou Eakan amounted to $3,620,335, $3,591,836, and $747,372 for the years ended December 31, 2013, 2012 and 2011, respectively.
			Prior to the signing of the agency contract with Guizhou Eakan, Guizhou Taibang provided processing services to Guizhou Eakan. Guizhou Taibang’s total income from processing services to Guizhou Eakan amounted to nil, nil and $243,563 for the years ended December 31, 2013, 2012 and 2011, respectively.
SCHEDULE OF RELATED PARTY TRANSACTIONS	'
	The material related party balances at December 31, 2013 and 2012 are presented as follows:
	Liabilities		Purpose		December 31, 2013			December 31, 2012
					USD			USD
	Other payable – a related party(1)		Commission			351,955			339,272
	Other payable – a related party(2)		Loan			2,383,472			2,311,044
	Other payable – a related party(3)		Contribution			2,929,903			-
	Other payable – related parties(4)		Contribution			1,541,640			1,431,308
	Total other payable – related parties					7,206,970			4,081,624
		-1	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. As of December 31, 2013 and 2012, Guizhou Taibang accrued commission payable of $351,955 and $339,272 for service rendered by Guizhou Eakan. The commission expense for service rendered by Guizhou Eakan amounted to $3,620,335, $3,591,836, and $747,372 for the years ended December 31, 2013, 2012 and 2011, respectively.
			Prior to the signing of the agency contract with Guizhou Eakan, Guizhou Taibang provided processing services to Guizhou Eakan. Guizhou Taibang’s total income from processing services to Guizhou Eakan amounted to nil, nil and $243,563 for the years ended December 31, 2013, 2012 and 2011, respectively.
		-2	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,383,472 and $2,311,044 as of December 31, 2013 and 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
		-3	In December 2013, Guizhou Taibang received a contribution of $2,929,903 from Guizhou Eakan Investing Corp. pending for the registration with the local AIC.
		-4	Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,541,640 and $1,431,308 as of December 31, 2013 and 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 20), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date of Jie’an contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $825,048) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $235,728) for the over-paid subscription and RMB2,937,473 (approximately $480,864) for the accrued interest and penalty as of December 31, 2013.

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
Net Income Loss Per Share Disclosure [Abstract]	'
SCHEDULE OF EPS - BASIC AND DILUTED	'
	The following table sets forth the computation of basic and diluted net income per share of common stock for the periods indicated:
		For the Years Ended
		December 31,		December 31,		December 31,
		2013		2012		2011
		USD		USD		USD
	Net income attributable to China Biologic Products, Inc.		54,601,551		45,222,189		18,181,710
	Earnings allocated to participating nonvested shares		-456,261		-69,624		-
	Net income allocated to common stockholders used in computing		54,145,290		45,152,565		18,181,710
	basic net income per common stock
	Interest on the notes		-		-		3,582,648
	Change in fair value of embedded conversion option in the notes		-		-		-6,289,661
	Change in fair value of warrants issued to investors and placement		-		-1,769,140		-5,685,173
	agent
	Net income used in diluted net income per common stock		54,145,290		43,383,425		9,789,524
	Weighted average shares used in computing basic net income per		26,410,819		26,153,540		25,028,796
	common stock
	Diluted effect of the notes		-		-		515,068
	Diluted effect of warrants issued to investors		-		212,792		551,686
	Diluted effect of stock option		1,161,292		473,391		559,112
	Weighted average shares used in computing diluted net income per		27,572,111		26,839,723		26,654,662
	common stock
	Net income per common stock – basic		2.05		1.73		0.73
	Net income per common stock – diluted		1.96		1.62		0.37

CHINA_BIOLOGIC_PRODUCTS_INC_PA1

CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY) (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
CONDENSED BALANCE SHEETS	'
	Condensed Balance Sheets:
		December 31, 2013		December 31, 2012
		USD		USD
	Cash		679,022		76,101
	Prepayments and prepaid expenses		87,548		95,486
	Property, plant and equipment, net		544		2,575
	Investment in and amounts due from subsidiaries		270,595,266		198,689,734
	Total Assets		271,362,380		198,863,896
	Other payables and accrued expenses		3,670,817		3,394,180
	Long-term loan		30,000,000		-
	Total Liabilities		33,670,817		3,394,180
	Total Equity		237,691,563		195,469,716
	Total Liabilities and Equity		271,362,380		198,863,896
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME	'
	Condensed Statements of Comprehensive Income:
		For the Years Ended
		December 31, 2013		December 31, 2012		December 31, 2011
		USD		USD		USD
	Equity in income of subsidiaries		62,457,106		51,063,576		19,848,119
	General and administrative expenses		-7,460,763		-8,048,993		-9,669,494
	Other expenses, net		-394,792		-34,543		-3,708,776
	Change in fair value of derivative liabilities		-		1,769,140		11,974,834
	Earnings before income tax expense		54,601,551		44,749,180		18,444,683
	Income tax benefit (expense)		-		473,009		-262,973
	Net Income		54,601,551		45,222,189		18,181,710
CONDENSED STATEMENTS OF CASH FLOWS	'
	Condensed Statements of Cash Flows:
		For the Years Ended
		December 31, 2013		December 31, 2012		December 31, 2011
		USD		USD		USD
	Net cash provided by (used in) operating activities		197,001		-160,272		-165,551
	Net cash used in investing activities		-		-		-1,970
	Net cash provided by (used in) financing activities		405,920		-		300,000
	Net increase (decrease) in cash		602,921		-160,272		132,479
	Cash at beginning of year		76,101		236,373		103,894
	Cash at end of year		679,022		76,101		236,373

DESCRIPTION_OF_BUSINESS_AND_SI1

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'
Total cash at banks and deposits including insured amount	$180,858,848	$129,289,461	'
Cash, Insured Amount	$679,022	$76,101	'
Customers that individually comprised 10% or more of the total sales	0	0	0
Suppliers that comprised 10% or more of the total purchases	0	0	2
Customers represented 10% or more of trade receivables	0	0	'
Suppliers that represented more than 10% of accounts payables	0	2	'
Human Albumin [Member]	'	'	'
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'
Major product sales percentage	44.10%	44.60%	54.50%
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'
Basis Of Presentation Significant Concentration And Risk [Line Items]	'	'	'
Major product sales percentage	38.00%	39.00%	32.30%

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended				12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)	CNY	Maximum [Member]	Minimum [Member]
Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Certificates of deposit	$74,352,540	$20,631,000	'	'	'	'
Equity method investment percentage	'	'	'	'	50.00%	20.00%
Contractual period of rights	'	'	'	'	'50 years	'40 years
Equity method impairment loss	0	0	0	'	'	'
Research and development expenses	4,223,165	3,032,719	3,978,233	'	'	'
Product liability insurance coverage	3,274,000	'	'	20,000,000	'	'
Loss on abandonment and write-off of long-lived assets	$0	$0	$6,603,028	'	'	'

SCHEDULE_OF_CASH_AND_CASH_EQUI

SCHEDULE OF CASH AND CASH EQUIVALENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]	'	'
Total	$143,726,562	$129,289,461
PRC, excluding Hong Kong [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Total	143,047,540	129,213,360
U.S. [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Total	$679,022	$76,101

SCHEDULE_OF_ESTIMATED_USEFUL_L

SCHEDULE OF ESTIMATED USEFUL LIVES OF THE ASSETS (Details)	12 Months Ended
	Dec. 31, 2013
Buildings [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives	'30 years
Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives	'10 years
Furniture, Fixtures, Office Equipment and Vehicles [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives	'10 years
Furniture, Fixtures, Office Equipment and Vehicles [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives	'5 years

SCHEDULE_OF_ESTIMATE_USEFUL_LI

SCHEDULE OF ESTIMATE USEFUL LIVES OF INTANGIBLE ASSETS (Details)	12 Months Ended
	Dec. 31, 2013
Permits and Licenses [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives of intangible assets	'10 years
GMP Certificate [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives of intangible assets	'5 years
Long-Term Customer-Relationship [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives of intangible assets	'4 years

SCHEDULE_OF_ACCOUNTS_RECEIVABL

SCHEDULE OF ACCOUNTS RECEIVABLE (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$17,730,821	$11,621,851
Less: Allowance for doubtful accounts	-460,689	-415,607
Total	$17,270,132	$11,206,244

SCHEDULE_OF_ACTIVITIES_IN_ALLO

SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning balance	$415,607	$414,092	$1,238,640
Provisions	31,567	0	0
Recoveries	0	-1,904	-19,611
Write-offs	0	0	-837,975
Foreign currency translation adjustment	13,515	3,419	33,038
Ending Balance	$460,689	$415,607	$414,092

INVENTORIES_Narrative_Details

INVENTORIES (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Write-down of obsolete inventories	$0	$0	$270,929

SCHEDULE_OF_INVENTORIES_Detail

SCHEDULE OF INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$47,400,578	$29,596,746
Work-in-process	20,720,666	24,524,142
Finished goods	20,513,611	21,558,285
Total	$88,634,855	$75,679,173

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Depreciation	$6,096,650	$5,792,418	$4,253,661
Interest expenses	$0	$0	$0

SCHEDULE_OF_PROPERTY_PLANT_AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	$76,775,260	$61,322,144
Accumulated depreciation	-25,658,760	-24,356,752
Total property, plant and equipment, net	51,116,500	36,965,392
Construction in progress	19,050,642	3,501,404
Prepayments for property, plant and equipment	2,981,930	10,858,381
Property, plant and equipment, net	73,149,072	51,325,177
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	31,714,173	25,183,496
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	36,919,094	29,625,166
Furniture, Fixtures, Office Equipment and Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property, plant and equipment, gross	$8,141,993	$6,513,482

INTANGIBLE_ASSETS_NET_Narrativ

INTANGIBLE ASSETS, NET (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Amortization expense for amortizing intangible assets	$1,196,279	$3,011,560	$3,270,131
2014	516,678	'	'
2015	514,884	'	'
2016	509,277	'	'
2017	474,897	'	'
2018	$431,726	'	'

SCHEDULE_OF_INTANGIBLE_ASSETS_

SCHEDULE OF INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$15,871,901	$15,247,052
Accumulated Amortization	-13,286,669	-11,705,470
Net carrying amount	2,585,232	3,541,582
Permits and Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted average amortization period	'10 years	'10 years
Gross carrying amount	5,144,788	4,987,647
Accumulated Amortization	-2,748,704	-2,119,622
Net carrying amount	2,396,084	2,868,025
GMP Certificate [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted average amortization period	'5 years	'5 years
Gross carrying amount	2,605,253	2,525,679
Accumulated Amortization	-2,605,253	-1,955,360
Net carrying amount	0	570,319
Long-Term Customer-Relationship [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted average amortization period	'4 years	'4 years
Gross carrying amount	7,756,106	7,519,206
Accumulated Amortization	-7,756,106	-7,519,206
Net carrying amount	0	0
Others [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	365,754	214,520
Accumulated Amortization	-176,606	-111,282
Net carrying amount	$189,148	$103,238

DEPOSITS_RELATED_TO_LAND_USE_R1

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
	USD ($)	CNY	USD ($)	CNY
Deposits related to land use rights	'	'	$13,235,580	83,400,000
Refunded deposits related to land use rights	2,128,100	13,000,000	'	'
Additional Refunded Deposits Related To Land Use Rights	$1,637,000	10,000,000	'	'

GOODWILL_Narrative_Details

GOODWILL (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Goodwill [Line Items]	'	'	'	'
Goodwill, Impairment Loss	$0	$0	$18,160,281	'
Implied fair value of goodwill	0	0	0	17,778,231
Loss on abandonment of property, plant and equipment	'	'	1,410,379	'
Loss On Write Off Of Collection Permits And Licenses	'	'	$5,192,649	'

SCHEDULE_OF_GOODWILL_Details

SCHEDULE OF GOODWILL (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill [Line Items]	'	'	'
Balance as of January 1	$0	$0	$17,778,231
Addition	0	0	0
Impairment loss	0	0	-18,160,281
Foreign currency exchange difference	0	0	382,050
Balance as of December 31	$0	$0	$0

RESTRICTED_CASH_AND_DEPOSIT_Na

RESTRICTED CASH AND DEPOSIT (Narrative) (Details)	12 Months Ended			0 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Nov. 01, 2012	Nov. 01, 2012	Dec. 31, 2013	Dec. 31, 2013	Aug. 07, 2013	Aug. 07, 2013
	USD ($)	CNY	USD ($)	Technical upgrade subsidy [Member]	Technical upgrade subsidy [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]	China Merchants Bank Beijing Branch [Member]
				USD ($)	CNY	USD ($)	CNY	USD ($)	CNY
Restricted Cash and Investments [Line Items]	'	'	'	'	'	'	'	'	'
Restricted cash and deposit	$30,523,674	'	$2,912,145	$2,912,145	18,350,000	'	'	'	'
Restricted cash and cash equivalent item agreement validity	'	'	'	'3 years	'3 years	'	'	'	'
Restricted cash used in the technical upgrade in respect of the new GMP standard	2,928,421	17,888,952	'	'	'	'	'	'	'
Restricted Time Deposits	'	'	'	'	'	30,448,200	186,000,000	30,000,000	186,000,000
Restricted Cash and Cash Equivalents	75,474	461,048	'	'	'	'	'	'	'
Deposit liabilities, collateral issued, financial instruments	'	'	'	'	'	'	'	$30,000,000	'

EQUITY_METHOD_INVESTMENT_Narra

EQUITY METHOD INVESTMENT (Narrative) (Details)	1 Months Ended
	Oct. 31, 2008	Oct. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
	USD ($)	CNY	USD ($)	USD ($)	Xian Huitian Blood Products Co., Ltd [Member]	Xian Huitian Blood Products Co., Ltd [Member]
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Equity Method Investment, Ownership Percentage	'	'	'	'	35.00%	35.00%
Payments to Acquire Equity Method Investments	$6,502,901	44,327,887	'	'	'	'
Other General and Administrative Expense	19,644	120,000	'	'	'	'
Excess Of Carrying Amount Over The Company Share Of Net Assets Of Equity Method Investees	'	'	2,076,329	2,722,915	'	'
Fair Value Adjustments For Property Plant And Equipment And Land Use Right	'	'	736,707	1,424,210	'	'
Equity Method Goodwill	'	'	$1,339,622	$1,298,705	'	'

BANK_LOANS_Narrative_Details

BANK LOANS (Narrative) (Details)

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 08, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 07, 2013

Aug. 07, 2013

Dec. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

USD ($)

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

China Merchants Bank Beijing Branch [Member]

Payables To Potential Investors [Member]

Payables To Potential Investors [Member]

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

Interest expense on short-term bank loans

$347,602

$446,381

$705,426

'

'

'

'

'

'

'

Interest-bearing deposit liabilities, Total

9,403,649

[1]

8,728,368

[1]

'

30,000,000

'

'

'

'

9,403,649

[1]

8,728,368

[1]

Loan lent period

'

'

'

'18 months

'

'

'

'

'

'

Debt instrument, interest rate terms

'

'

'

'3-month

'

'

'

'

'

'

Line of credit facility, interest rate description

'

'

'

'3-month LIBOR plus 1.6%

'

'

'

'

'

'

Line of credit facility, commitment fee percentage

'

'

'

0.70%

'

'

'

'

'

'

Restricted Time Deposits

'

'

'

'

$30,448,200

186,000,000

$30,000,000

186,000,000

'

'

[1]

The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.

SCHEDULE_OF_SHORTTERM_BANK_LOA

SCHEDULE OF SHORT-TERM BANK LOANS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Short-term Debt [Line Items]	'	'
Short-term Debt	$9,822,000	$7,935,000
Unsecured Loan 1 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	1-Aug-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	3,174,000
Unsecured Loan 2 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	3-Sep-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	3,174,000
Unsecured Loan 3 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	3-Sep-13	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	0	1,587,000
Unsecured Loan 4 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	12-May-14	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	4,911,000	0
Unsecured Loan 5 [Member]	'	'
Short-term Debt [Line Items]	'	'
Maturity date	22-Dec-14	'
Annual interest rate	6.00%	'
Unsecured Debt, Current	$4,911,000	$0

SCHEDULE_OF_OTHER_PAYABLES_AND

SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Accounts Payable And Accrued Liabilities [Line Items]	'		'
Payables to potential investors (1)	$9,403,649	[1]	$8,728,368	[1]
Salaries and bonuses payable	8,217,129		6,868,908
Accruals for selling commission and promotion fee	3,566,693		3,476,215
Dividends payable to noncontrolling interest	1,411,094		0
Payables for construction work	4,427,423		347,877
Other tax payables	2,119,024		2,180,643
Others	5,707,728		3,821,338
Total	$34,852,740		$25,423,349
[1]	The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.

OTHER_PAYABLES_AND_ACCRUED_EXP2

OTHER PAYABLES AND ACCRUED EXPENSES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2010	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2007	Dec. 31, 2007
	USD ($)	CNY	USD ($)		USD ($)		Deposits Received From Potential Strategic Investors [Member]	Deposits Received From Potential Strategic Investors [Member]	Aggregate Amount Received From Certain Potential Strategic Investors In Connection With Their Subscription To Purchase Shares In Guizhou Taibang [Member]	Aggregate Amount Received From Certain Potential Strategic Investors In Connection With Their Subscription To Purchase Shares In Guizhou Taibang [Member]
							USD ($)	USD ($)	USD ($)	CNY
Accounts Payable And Accrued Liabilities [Line Items]	'	'	'		'		'	'	'	'
Payables to potential investors	'	'	$9,403,649	[1]	$8,728,368	[1]	$6,508,712	$6,309,912	$7,506,408	50,960,000
Interest on these deposits	'	'	2,894,937		2,418,456		'	'	'	'
Company Refunded Deposits	$1,699,040	11,200,000	'		'		'	'	'	'
[1]	The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.

INCOME_TAX_Narrative_Details

INCOME TAX (Narrative) (Details)

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

36 Months Ended

120 Months Ended

Jan. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2020

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

CNY

PRC [Member]

The United States of America [Member]

The United States of America [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

CBP [Member]

Hong Kong [Member]

Hong Kong [Member]

Hong Kong [Member]

Shandong Taibang [Member]

Shandong Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

PRC subsidiaries [Member]

PRC subsidiaries [Member]

PRC subsidiaries [Member]

PRC subsidiaries [Member]

PRC subsidiaries [Member]

PRC subsidiaries [Member]

USD ($)

USD ($)

2027 [Member]

2026 [Member]

2031 [Member]

2028 [Member]

2029 [Member]

2030 [Member]

2032 [Member]

2033 [Member]

USD ($)

Scenario, Forecast [Member]

USD ($)

USD ($)

2015 [Member]

2016 [Member]

2017 [Member]

2018 [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Income Tax Rate

'

'

'

'

'

25.00%

'

35.00%

'

'

'

'

'

'

'

'

'

'

16.50%

16.50%

16.50%

'

'

'

'

'

'

'

'

'

'

Preferential tax rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

15.00%

15.00%

15.00%

'

'

'

'

'

'

Deferred tax assets for tax loss carryforwards

'

$8,950,323

$7,078,822

'

'

'

'

'

$4,219,482

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,730,841

'

'

'

'

'

Tax loss carryforwards

'

'

'

'

'

'

'

'

12,410,240

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,923,363

'

'

'

'

'

Tax loss carryforwards expiring

'

'

'

'

'

'

'

'

'

'

614,982

1,268,307

3,382,154

1,113,597

1,405,718

2,350,326

978,837

1,296,319

'

'

'

'

'

'

'

'

'

1,153,544

5,220,932

7,180,046

5,368,841

Deferred Tax Assets, Valuation Allowance

'

'

'

'

'

'

'

'

2,827,749

2,587,892

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,730,841

3,300,089

'

'

'

'

Increase (Decrease) in valuation allowances deferred tax assets

'

1,588,875

-1,280,005

830,497

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subject to withholding tax at 10%, unless reduced by tax treaties

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

U.S. federal income tax

'

'

'

'

'

'

34.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Undistributed earnings

'

162,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

Deferred tax liabilities

'

2,467,760

1,955,186

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underpayment of taxes

'

$15,000

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SCHEDULE_OF_EARNINGS_LOSSES_BE

SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
PRC, excluding Hong Kong	$98,401,673	$84,980,477	$42,616,865
U.S.	-7,855,555	-6,314,398	-1,403,437
BVI	2,116,243	2,538,030	1,645,364
Hong Kong	-260,996	-68,970	-575,924
Earnings before income tax expense	$92,401,365	$81,135,139	$42,282,868

SCHEDULE_OF_INCOME_TAX_EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current income tax expense	$15,427,669	$14,035,714	$13,494,616
Deferred tax expense (benefit)	112,632	1,127,433	-2,595,103
Income Tax Expense (Benefit)	$15,540,301	$15,163,147	$10,899,513

SCHEDULE_OF_RECONCILIATION_OF_

SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
PRC statutory income tax rate	25.00%	25.00%	25.00%
Non-taxable income	0.00%	-0.70%	-2.30%
Non-deductible expenses:	'	'	'
Share-based compensation	0.90%	1.90%	3.90%
Impairment loss on goodwill	0.00%	0.00%	10.70%
Loss on write-off of long-lived assets	0.00%	0.00%	0.80%
Others	0.70%	0.40%	0.70%
Tax rate differential	-1.00%	-1.20%	1.60%
Effect of change in tax rate on deferred tax	0.00%	0.00%	-1.80%
Effect of PRC preferential tax rate	-12.70%	-11.00%	-18.20%
Bonus deduction on research and development expenses	-1.40%	-1.30%	-1.20%
Change in valuation allowance	1.70%	0.70%	2.00%
PRC dividend withholding tax	2.80%	4.00%	3.10%
Tax effect of equity method investment	0.80%	0.90%	1.50%
Effective income tax rate	16.80%	18.70%	25.80%

SCHEDULE_OF_DEFERRED_TAX_ASSET

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets arising from:	'	'
-Accrued expenses	$2,065,310	$1,841,210
-Tax loss carryforwards	8,950,323	7,078,822
Gross deferred tax assets	11,015,633	8,920,032
Less: valuation allowance	-7,558,590	-5,887,981
Net deferred tax assets	3,457,043	3,032,051
Deferred tax liabilities arising from:	'	'
- Intangible assets	-548,651	-498,987
- Property, plant and equipment	0	-198,443
- Equity method investment	-1,391,733	-1,190,841
- Dividend withholding tax	-2,467,760	-1,955,186
Deferred tax liabilities	-4,408,144	-3,843,457
Classification on consolidated balance sheets:	'	'
Deferred tax assets - current, net (included in prepayments and other current assets)	2,065,310	1,841,210
Deferred tax liabilities - non-current, net (included in other liabilities)	($3,016,411)	($2,652,616)

WARRANTS_OPTIONS_AND_NONVESTED2

WARRANTS, OPTIONS AND NONVESTED SHARES (Narrative) (Details) (USD $)	1 Months Ended	12 Months Ended								1 Months Ended
	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	9-May-08
					For the year ended December 31, 2011, stock options to purchase an aggregate of 175,000 common stock were granted [Member]	For the year ended December 31, 2012, stock options to purchase an aggregate of 900,000 common stock were granted [Member]	For the year ended December 31, 2012, stock options to purchase an aggregate of 900,000 common stock were granted [Member]	For the year ended December 31, 2012, stock options to purchase an aggregate of 900,000 common stock were granted [Member]	For the year ended December 31, 2013, stock options to purchase an aggregate of 33,000 common stock were granted [Member]	2008 Equity Incentive Plan [Member]
					Directors and employees at exercise prices ranging from $5.97 to $17.00 per share with vesting periods of 1 year [Member]	Directors and employees at exercise prices ranging from $9.16 to $9.85 per share with vesting periods ranging from 1 year to 4 years [Member]	Directors and employees at exercise prices ranging from $9.16 to $9.85 per share with vesting periods ranging from 1 year to 4 years [Member]	Directors and employees at exercise prices ranging from $9.16 to $9.85 per share with vesting periods ranging from 1 year to 4 years [Member]	Directors and employees at exercise prices ranging from $4.00 to $12.26 which vested immediately [Member]
							Maximum [Member]	Minimum [Member]
Warrants and Options Disclosure [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of Options, Granted	'	33,000	900,000	175,000	175,000	900,000	'	'	33,000	'
Stock compensation expense related to options	'	$3,773,073	$4,335,595	$4,896,232	'	'	'	'	'	'
Weighted average grant date fair value of options granted	'	$8.37	$7.58	$8.95	'	'	'	'	'	'
Aggregate fair value of options granted	'	276,250	6,817,649	1,566,250	'	'	'	'	'	'
Stock compensation expense with respect to non-vested stock option	'	3,654,022	'	'	'	'	'	'	'	'
Stock compensation expense to be recognized with respect to non-vested stock option	'	'2 years 2 months 19 days	'	'	'	'	'	'	'	'
Stock compensation expense related to nonvested shares	'	1,277,723	209,332	'	'	'	'	'	'	'
Stock compensation expense to be recognized with respect to non-vested shares	'	6,724,915	'	'	'	'	'	'	'	'
Stock compensation expense with respect to non-vested shares weighted average vesting period	'	'3 years 2 months 16 days	'	'	'	'	'	'	'	'
Company issued warrants to purchase shares of its common stock to the investors	'	'	'	1,194,268	'	'	'	'	'	'
Company issued warrants to purchase shares of its common stock to the placement agent	'	'	'	93,750	'	'	'	'	'	'
Warrants to purchase common stock	937,500	'	'	'	'	'	'	'	'	'
Proceeds from warrant exercises	$4,500,000	'	'	'	'	'	'	'	'	'
Vesting period	'	'	'	'	'1 year	'	'4 years	'1 year	'	'
Exercise price range, Lower range limit	'	'	'	'	$5.97	$9.16	'	'	$4	'
Exercise price range, Upper range limit	'	'	'	'	$17	$9.85	'	'	$12.26	'
Stock Incentive Option Granted Percentage	'	'	'	'	'	'	'	'	'	10.00%
Fair Value Market Exercise Price Percentage	'	'	'	'	'	'	'	'	'	110.00%
Options granted terms	'	'	'	'	'	'	'	'	'	'10 years

SCHEDULE_OF_WARRANT_ACTIVITIES

SCHEDULE OF WARRANT ACTIVITIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule Of Warrant Activities [Line Items]	'	'	'	'
Warrants Outstanding, Beginning of Period	0	937,500	937,500	'
Warrants Outstanding, Weighted Average Exercise Price, Beginning of Period	$0	$4.80	$4.80	'
Warrants Outstanding, Weighted Average Remaining Contractual Term	'0 years	'0 years	'5 months 8 days	'1 year 5 months 8 days
Warrants Granted in Period	0	0	0	'
Warrants Granted in Period, Weighted Average Exercise Price	$0	$0	$0	'
Warrants Granted in Period, Weighted Average Remaining Contractual Term	'0 years	'0 years	'0 years	'
Warrants Exercised in Period	0	-937,500	0	'
Warrants Exercised in Period, Weighted Average Exercise Price	$0	$4.80	$0	'
Warrants Exercised in Period, Weighted Average Remaining Contractual Term	'0 years	'0 years	'0 years	'
Warrants Outstanding, Ending of Period	0	0	937,500	937,500
Warrants Outstanding, Weighted Average Exercise Price, Ending of Period	$0	$0	$4.80	$4.80

SCHEDULE_OF_WARRANTS_VALUATION

SCHEDULE OF WARRANTS VALUATION (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013
		Warrants exercised June 6, 2012 [Member]	Warrants exercised June 4, 2012 [Member]
Schedule Of Warrants Valuation [Line Items]	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	0.05%	0.05%	0.04%
Time to maturity (in years)	'5 months 5 days	'0 years	'0 years
Expected volatility	80.00%	47.40%	37.30%
Fair value of underlying common shares (per share)	$10.46	$9.22	$8.55

SCHEDULE_OF_CHANGE_IN_FAIR_VAL

SCHEDULE OF CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule Of Change In Fair Value Of Derivative Liabilities [Line Items]	'	'	'	'
Fair Value	'	$0	$5,410,419	$25,657,253
Increase (decrease) in fair value for the year ended	'	-1,769,140	-11,974,834	'
Fair value at date of warrants exercise	'	-3,641,279	0	'
Fair value at date of notes conversion	'	'	-8,272,000	'
Embedded conversion option in the notes [Member]	'	'	'	'
Schedule Of Change In Fair Value Of Derivative Liabilities [Line Items]	'	'	'	'
Fair Value	'	'	0	14,561,661
Increase (decrease) in fair value for the year ended	0	0	-6,289,661	'
Fair value at date of warrants exercise	'	'	0	'
Fair value at date of notes conversion	'	'	-8,272,000	'
Warrants issued to investors [Member]	'	'	'	'
Schedule Of Change In Fair Value Of Derivative Liabilities [Line Items]	'	'	'	'
Fair Value	'	0	5,410,419	11,095,592
Increase (decrease) in fair value for the year ended	0	-1,769,140	-5,685,173	'
Fair value at date of warrants exercise	'	-3,641,279	0	'
Fair value at date of notes conversion	'	'	$0	'

SCHEDULE_OF_STOCK_OPTIONS_ACTI

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock Option Activity [Line Items]	'	'	'	'
Outstanding, Number of Options	2,648,609	1,994,600	1,906,600	'
Outstanding, Weighted Average Exercise Price	$9.39	$9.24	$8.50	'
Outstanding, Weighted Average Remaining Contractual Term in Years	'7 years 2 months 12 days	'7 years 7 months 24 days	'7 years 8 months 16 days	'8 years 6 months 18 days
Outstanding, Aggregate Intrinsic Value	$18,374,422	$5,197,076	$15,039,114	'
Number of Options, Granted	33,000	900,000	175,000	'
Weighted Average Exercise Price, Granted	$10.48	$9.61	$15.28	'
Number of Options, Exercised	-648,379	-90,990	-75,000	'
Weighted Average Exercise Price, Exercised	$8.32	$7.99	$4	'
Aggregate Intrinsic Value, Exercised	-10,923,644	-468,322	-635,250	'
Number of Options, Forfeited and expired	-150,854	-155,001	-12,000	'
Weighted Average Exercise Price, Forfeited and expired	$6.78	$9.69	$12.26	'
Outstanding, Number of Options	1,882,376	2,648,609	1,994,600	1,906,600
Outstanding, Weighted Average Exercise Price	$9.98	$9.39	$9.24	$8.50
Outstanding, Aggregate Intrinsic Value	35,518,897	18,374,422	5,197,076	15,039,114
Number of Options, Vested and expected to vest	1,882,376	'	'	'
Weighted Average Exercise Price, Vested and expected to vest	$9.98	'	'	'
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	'7 years 2 months 12 days	'	'	'
Vested and expected to vest, Aggregate Intrinsic Value	35,518,897	'	'	'
Number of Options, Exercisable	1,357,376	'	'	'
Weighted Average Exercise Price, Exercisable	$10.10	'	'	'
Weighted Average Remaining Contractual Term in Years, Exercisable	'6 years 8 months 8 days	'	'	'
Aggregate Intrinsic Value, Exercisable	$25,450,897	'	'	'

SCHEDULE_OF_STOCK_OPTIONS_VALU

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTION (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Expected volatility	104.00%	104.00%	69.43%
Expected dividends yield	0.00%	0.00%	0.00%
Expected term (in years)	'5 years 4 months 17 days	'6 years 4 days	'5 years
Risk-free interest rate	0.72%	0.82%	1.92%
Fair value of underlying common stock (per share)	$10.48	$9.61	$15.28

SCHEDULE_OF_NONVESTED_SHARES_A

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) (Non Vested Shares [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Non Vested Shares [Member]	'	'
Number of nonvested shares, Outstanding	120,000	0
Grant date weighted average fair value, Outstanding	$9.85	$0
Number of nonvested shares, Granted	306,500	120,000
Grant date weighted average fair value, Granted	$22.94	$9.85
Number of nonvested shares, Vested	-63,750	0
Grant date weighted average fair value, Vested	$9.85	$0
Number of nonvested shares, Forfeited	0	0
Grant date weighted average fair value, Forfeited	$0	$0
Number of nonvested shares, Outstanding	362,750	120,000
Grant date weighted average fair value, Outstanding	$20.91	$9.85

STOCKHOLDER_RIGHTS_PLAN_Narrat

STOCKHOLDER RIGHTS PLAN (Narrative) (Details) (USD $)	1 Months Ended
	Nov. 30, 2012	Dec. 31, 2013
		Series A Participating Preferred Stock [Member]
Stockholders Rights Plan [Line Items]	'	'
Shareholder Right Exercise Price	$60	'
Series A Participating Preferred Stock	'	1,000,000
Rights become exercisable if a person or group acquires 10 or more of the Company	10.00%	'
10% threshold	10.00%	'
Rights would become exercisable if at any time after this announcement the stockholder increases its ownership percentage by 2%	2.00%	'
If after a person or group acquires 10% or more of the Companys outstanding common stock, the Company merges into another company	10.00%	'
An acquiring entity merges into the Company or the Company sells or transfers more than 50% of its assets	50.00%	'
May redeem the rights for $0.001 per right	$0.00	'

STATUTORY_RESERVES_Narrative_D

STATUTORY RESERVES (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statutory Accounting Practices [Line Items]	'	'
Allocate at least 10% of its after tax profits	10.00%	'
Until the reserve balance reaches 50%	50.00%	'
Accumulated balance of the statutory reserve	$30,796,531	$30,772,993

SHARE_REPURCHASE_Narrative_Det

SHARE REPURCHASE (Narrative) (Details) (USD $)	0 Months Ended
	Aug. 08, 2013
Accelerated Share Repurchases [Line Items]	'
Treasury Stock, Shares, Acquired	1,479,704
Treasury Stock Value Acquired	$29,594,080

SCHEDULE_OF_SALES_BY_PRODUCT_T

SCHEDULE OF SALES BY PRODUCT TYPE (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Product Information [Line Items]	'	'	'
Sales	$203,356,856	$184,813,495	$153,092,289
Human Albumin [Member]	'	'	'
Product Information [Line Items]	'	'	'
Sales	89,671,619	82,450,825	83,433,691
Human Immunoglobulin For Intravenous Injection [Member]	'	'	'
Product Information [Line Items]	'	'	'
Sales	77,341,616	72,005,196	49,482,514
Other Immunoglobulin Products [Member]	'	'	'
Product Information [Line Items]	'	'	'
Sales	19,682,927	19,377,603	16,669,069
Placenta Polypeptide [Member]	'	'	'
Product Information [Line Items]	'	'	'
Sales	12,150,539	10,088,754	1,935,428
Others [Member]	'	'	'
Product Information [Line Items]	'	'	'
Sales	$4,510,155	$891,117	$1,571,587

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)

Dec. 31, 2013

Apr. 30, 2013

Apr. 30, 2013

31-May-09

Jun. 30, 2007

Mar. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Nov. 30, 2010

Nov. 30, 2010

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2011

31-May-07

31-May-07

USD ($)

USD ($)

CNY

Equity Purchase Agreements [Member]

Equity Purchase Agreements [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Capital commitment,amount committed

$4,619,975

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91% controlling interest of Guizhou Taibang's shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91.00%

91.00%

Issuance of an additional 20,000,000 shares of Guizhou Taibang

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Shares price of additionally issued shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.8

Remaining 9% noncontrolling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

9.00%

Investors agreed to invest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,475,832

50,960,000

Exchange for 18,200,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,200,000

18,200,000

21.4%, of Guizhou Taibang's equity interests

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21.40%

21.40%

Subscribed for 1,800,000 shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

1,800,000

Share of the 20,000,000 shares being offered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

Right to acquire common stock shares

'

'

'

'

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Denied the rights of first refusal of Jieban over the 18,200,000 shares

'

'

'

18,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC

'

'

'

'

'

1,800,000

'

'

'

'

1,800,000

'

'

'

'

'

'

Related interest and penalty from May 2007 to December 2011 amounting to RMB 25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

3,967,500

25,000,000

'

'

Return over - paid subscription

'

'

'

'

'

'

'

'

'

'

'

'

'

228,528

1,440,000

'

'

Interest and penalty, amounting to RMB 10,000,000 (approximately $1,587,000) in aggregate

'

'

'

'

'

'

'

'

'

'

'

'

'

1,587,000

10,000,000

'

'

Dalins ownership in Guizhou Taibang will be diluted from 54%

'

'

'

'

'

'

'

'

'

'

'

54.00%

54.00%

'

'

'

'

Diluted to 52.54%

'

'

'

'

'

'

'

'

'

'

'

52.54%

52.54%

'

'

'

'

Payables to Jie'an for the additional funds received

'

'

'

'

'

'

'

'

'

'

'

825,048

5,040,000

'

'

'

'

Payables to Jie'an for over-paid subscription

'

'

'

'

'

'

'

'

'

'

'

235,728

1,440,000

'

'

'

'

Payable to Jie'an for the accrued interest

'

'

'

'

'

'

'

'

'

'

'

480,864

2,937,473

'

'

'

'

Company returned proceeds

'

'

'

'

'

'

'

'

1,699,040

11,200,000

'

'

'

'

'

'

'

Request for distribution of dividends of $2,990,943 (or RMB 18,349,345)

'

'

'

'

'

'

2,990,943

18,349,345

'

'

'

'

'

'

'

'

'

Request for interest in amount of $464,061 (or RMB 2,847,000)

'

'

'

'

'

'

464,061

2,847,000

'

'

'

'

'

'

'

'

'

Accrued Interest

'

'

'

'

'

'

'

'

'

'

'

2,811,516

17,174,807

'

'

'

'

Penalty

'

'

'

'

'

'

'

'

'

'

'

83,422

509,600

'

'

'

'

Penalty Imposed By The Agreement

'

'

'

'

'

'

'

'

'

'

'

1.00%

1.00%

'

'

'

'

Gain Contingency, Unrecorded Amount

'

$6,064,800

38,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Share data in Millions, unless otherwise specified

USD ($)

USD ($)

Guizhou Eakan [Member]

Jiean [Member]

Jiean [Member]

Guizhou Eakan Investing Corp [Member]

Guizhou Eakan Investing Corp [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Guizhou Taibang [Member]

Commission [Member]

Commission [Member]

Commission [Member]

USD ($)

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

CNY

Guizhou Eakan [Member]

Guizhou Eakan [Member]

Guizhou Eakan [Member]

USD ($)

USD ($)

USD ($)

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commission Payable

$351,955

$339,272

'

'

'

'

'

'

'

'

'

'

'

'

Commission expense for service rendered

'

'

'

'

'

'

'

'

'

'

'

3,620,335

3,591,836

747,372

Income from processing services

'

'

243,563

'

'

'

'

'

'

'

'

'

'

'

Payables to Guizhou Eakan Investing Corp.

'

'

'

'

'

2,383,472

2,311,044

'

'

'

'

'

'

'

Guizhou Taibang received additional contributions

'

'

'

'

'

'

'

'

2,929,903

962,853

6,480,000

'

'

'

Payables to Jie'an Noncontrolling Interest

1,541,640

1,431,308

'

'

'

'

'

'

'

'

'

'

'

'

Maintain Jie'an equity interest in Guizhou Taibang at 9%

'

'

'

'

'

'

'

'

'

9.00%

9.00%

'

'

'

Jieban requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC

'

'

'

'

'

'

'

1.8

'

'

'

'

'

'

Dalins ownership in Guizhou Taibang will be diluted from 54%

'

'

'

'

'

'

'

'

54.00%

'

'

'

'

'

Ownership in Guizhou Taibang will be diluted to 52.54%

'

'

'

'

'

'

'

'

52.54%

'

'

'

'

'

Jie'an's additional fund

'

'

'

825,048

5,040,000

'

'

'

'

'

'

'

'

'

Payables to Jie'an for over-paid subscription

'

'

'

235,728

1,440,000

'

'

'

'

'

'

'

'

'

Accrued interest and penalty for Jie'an's additional fund

'

'

'

$480,864

2,937,473

'

'

'

'

'

'

'

'

'

SCHEDULE_OF_MATERIAL_RELATED_P

SCHEDULE OF MATERIAL RELATED PARTY TRANSACTIONS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Related Party Transactions [Line Items]	'		'		'
Sales of products to related parties	$0	[1]	$0	[1]	$243,563	[1]
Commission expenses with related parties	$3,620,335	[1]	$3,591,836	[1]	$747,372	[1]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (bGuizhou Eakanb), an affiliate of one of the Guizhou Taibangbs noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. As of December 31, 2013 and 2012, Guizhou Taibang accrued commission payable of $351,955 and $339,272 for service rendered by Guizhou Eakan. The commission expense for service rendered by Guizhou Eakan amounted to $3,620,335, $3,591,836, and $747,372 for the years ended December 31, 2013, 2012 and 2011, respectively. Prior to the signing of the agency contract with Guizhou Eakan, Guizhou Taibang provided processing services to Guizhou Eakan. Guizhou Taibangbs total income from processing services to Guizhou Eakan amounted to nil, nil and $243,563 for the years ended December 31, 2013, 2012 and 2011, respectively.

SCHEDULE_OF_RELATED_PARTY_TRAN

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	$7,206,970		$4,081,624
Commission [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	351,955	[1]	339,272	[1]
Loan [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	2,383,472	[2]	2,311,044	[2]
Contribution One [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	2,929,903	[3]	0	[3]
Contribution Two [Member]	'		'
Related Party Transaction [Line Items]	'		'
Total other payable - related parties	$1,541,640	[4]	$1,431,308	[4]
[1]	During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (bGuizhou Eakanb), an affiliate of one of the Guizhou Taibangbs noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. As of December 31, 2013 and 2012, Guizhou Taibang accrued commission payable of $351,955 and $339,272 for service rendered by Guizhou Eakan. The commission expense for service rendered by Guizhou Eakan amounted to $3,620,335, $3,591,836, and $747,372 for the years ended December 31, 2013, 2012 and 2011, respectively. Prior to the signing of the agency contract with Guizhou Eakan, Guizhou Taibang provided processing services to Guizhou Eakan. Guizhou Taibangbs total income from processing services to Guizhou Eakan amounted to nil, nil and $243,563 for the years ended December 31, 2013, 2012 and 2011, respectively.
[2]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,383,472 and $2,311,044 as of December 31, 2013 and 2012, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
[3]	In December 2013, Guizhou Taibang received a contribution of $2,929,903 from Guizhou Eakan Investing Corp. pending for the registration with the local AIC.
[4]	Guizhou Taibang has payables to Jieban, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,541,640 and $1,431,308 as of December 31, 2013 and 2012, respectively. In 2007, Guizhou Taibang received additional contributions from Jieban of $962,853 (or RMB6,480,000) to maintain Jiebanbs equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 20), the contribution is subject to be returned to Jieban. During the second quarter of 2010, Jieban requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholdersb meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholdersb approval of Jiebanbs request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalinbs ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jieban will be entitled to receive its pro rata share of Guizhou Taibangbs profits since the date of Jieban contribution became effective. As this case is closely tied to the outcome of the strategic investorsb dispute stated above, the Company has recorded, in its balance sheet, payables to Jieban in the amounts of RMB5,040,000 (approximately $825,048) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $235,728) for the over-paid subscription and RMB2,937,473 (approximately $480,864) for the accrued interest and penalty as of December 31, 2013.

NET_INCOME_PER_SHARE_Narrative

NET INCOME PER SHARE (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options excluded from the calculation of diluted net income per share of common stock	0	1,938,009	1,164,000
Average exercise price of options excluded from the calculation of diluted net income per share of common stock	'	$11.34	$12.84

SCHEDULE_OF_NET_INCOME_PER_SHA

SCHEDULE OF NET INCOME PER SHARE RECONCILIATION (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income attributable to China Biologic Products, Inc.	$54,601,551	$45,222,189	$18,181,710
Earnings allocated to participating nonvested shares	-456,261	-69,624	0
Net income allocated to common stockholders used in computing basic net income per common stock	54,145,290	45,152,565	18,181,710
Interest on the notes	0	0	3,582,648
Change in fair value of derivative liabilities	'	-1,769,140	-11,974,834
Net income used in diluted net income per common stock	54,145,290	43,383,425	9,789,524
Embedded conversion option in the notes [Member]	'	'	'
Change in fair value of derivative liabilities	0	0	-6,289,661
Warrants issued to investors and placement agent [Member]	'	'	'
Change in fair value of derivative liabilities	$0	($1,769,140)	($5,685,173)

SCHEDULE_OF_NET_INCOME_PER_SHA1

SCHEDULE OF NET INCOME PER SHARE - BASIC AND DILUTED (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Weighted average shares used in computing basic net income per common stock	26,410,819	26,153,540	25,028,796
Diluted effect of the notes	0	0	515,068
Diluted effect of warrants issued to investors	0	212,792	551,686
Diluted effect of stock option	1,161,292	473,391	559,112
Weighted average shares used in computing diluted net income per common stock	27,572,111	26,839,723	26,654,662
Net income per common stock - basic	$2.05	$1.73	$0.73
Net income per common stock - diluted	$1.96	$1.62	$0.37

SCHEDULE_OF_CONDENSED_BALANCE_

SCHEDULE OF CONDENSED BALANCE SHEETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Financial information Disclosure [Line Items]	'	'	'	'
Cash and cash equivalents	$144,138,487	$129,609,317	$89,411,835	$64,941,368
Property, plant and equipment, net	73,149,072	51,325,177	'	'
Total Assets	403,781,207	311,047,150	'	'
Other payables and accrued expenses	34,852,740	25,423,349	'	'
Total Liabilities	99,811,598	53,627,986	'	'
Total Equity	237,691,563	195,469,716	'	'
Total Liabilities and Equity	403,781,207	311,047,150	'	'
Parent [Member]	'	'	'	'
Financial information Disclosure [Line Items]	'	'	'	'
Cash and cash equivalents	679,022	76,101	236,373	103,894
Prepayments and prepaid expenses	87,548	95,486	'	'
Property, plant and equipment, net	544	2,575	'	'
Investment in and amounts due from subsidiaries	270,595,266	198,689,734	'	'
Total Assets	271,362,380	198,863,896	'	'
Other payables and accrued expenses	3,670,817	3,394,180	'	'
Long-term loan	30,000,000	0	'	'
Total Liabilities	33,670,817	3,394,180	'	'
Total Equity	237,691,563	195,469,716	'	'
Total Liabilities and Equity	$271,362,380	$198,863,896	'	'

SCHEDULE_OF_CONDENSED_STATEMEN

SCHEDULE OF CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statements Of Comprehensive Income [Line Items]	'	'	'
Equity in income of an equity method investee	$2,170,473	$2,665,881	$1,858,171
General and administrative expenses	-36,073,871	-34,034,360	-31,519,824
Change in fair value of derivative liabilities	0	1,769,140	11,974,834
Earnings before income tax expense	92,401,365	81,135,139	42,282,868
Income tax benefit (expense)	-15,540,301	-15,163,147	-10,899,513
Net Income	76,861,064	65,971,992	31,383,355
Parent [Member]	'	'	'
Statements Of Comprehensive Income [Line Items]	'	'	'
Equity in income of an equity method investee	62,457,106	51,063,576	19,848,119
General and administrative expenses	-7,460,763	-8,048,993	-9,669,494
Other expenses, net	-394,792	-34,543	-3,708,776
Change in fair value of derivative liabilities	0	1,769,140	11,974,834
Earnings before income tax expense	54,601,551	44,749,180	18,444,683
Income tax benefit (expense)	0	473,009	-262,973
Net Income	$54,601,551	$45,222,189	$18,181,710

SCHEDULE_OF_STATEMENTS_OF_CASH

SCHEDULE OF STATEMENTS OF CASH FLOWS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statements Of Cash Flows [Line Items]	'	'	'
Net cash provided by (used in) operating activities	$74,302,995	$71,097,317	$38,469,919
Net cash used in investing activities	-25,567,595	-26,753,193	-7,127,252
Net cash provided by (used in) financing activities	-38,524,650	-5,104,076	-10,076,504
Net increase (decrease) in cash	14,529,170	40,197,482	24,470,467
Cash and cash equivalents at beginning of year	129,609,317	89,411,835	64,941,368
Cash and cash equivalents at end of year	144,138,487	129,609,317	89,411,835
Parent [Member]	'	'	'
Statements Of Cash Flows [Line Items]	'	'	'
Net cash provided by (used in) operating activities	197,001	-160,272	-165,551
Net cash used in investing activities	0	0	-1,970
Net cash provided by (used in) financing activities	405,920	0	300,000
Net increase (decrease) in cash	602,921	-160,272	132,479
Cash and cash equivalents at beginning of year	76,101	236,373	103,894
Cash and cash equivalents at end of year	$679,022	$76,101	$236,373

SUBSEQUENT_EVENT_Narrative_Det

SUBSEQUENT EVENT (Narrative) (Details)	Dec. 31, 2013		Dec. 31, 2012		Jan. 27, 2014	Feb. 25, 2014	Feb. 25, 2014	Feb. 25, 2014	Feb. 25, 2014	Feb. 25, 2014
	USD ($)		USD ($)		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
					USD ($)	China Merchants Bank New York Branch [Member]	24 Month Loan [Member]	24 Month Loan [Member]	18 Month Loan [Member]	18 Month Loan [Member]
							China Merchants Bank New York Branch [Member]	China Merchants Bank New York Branch [Member]	China Merchants Bank New York Branch [Member]	China Merchants Bank New York Branch [Member]
							USD ($)	CNY	USD ($)	CNY
Subsequent Event [Line Items]	'		'		'	'	'	'	'	'
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	'		'		2,500,000	'	'	'	'	'
Stock Repurchase Program, Authorized Amount	'		'		$70,000,000	'	'	'	'	'
Interest-bearing Deposit Liabilities, Total	9,403,649	[1]	8,728,368	[1]	'	'	40,000,000	'	30,000,000	'
Restricted Time Deposits	'		'		'	'	$40,352,050	246,500,000	$31,856,020	194,600,000
Line of Credit Facility, Interest Rate Description	'		'		'	'3-month LIBOR plus 1.3%	'	'	'	'
Line of Credit Facility, Commitment Fee Percentage	'		'		'	1.20%	'	'	'	'
[1]	The payables to potential investors comprise deposits received from potential strategic investors of $6,508,712 and $6,309,912 as of December 31, 2013 and 2012, respectively, and related interest plus penalty on these deposits totaling $2,894,937 and $2,418,456 as of December 31, 2013 and 2012, respectively.